Stockwinners Market Radar for March 30, 2022 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:11 EDT Cathie Wood's ARK Investment bought 96.6K shares of Coinbase today

19:04 EDT FDA AdCom votes 4-yes, 6-no on efficacy of Amylyx's AMX0035 in ALS - Amylyx Pharmaceutical announced the outcome of the FDA Peripheral and Central Nervous System Drugs Advisory Committee meeting to review the Company's New Drug Application for AMX0035, or sodium phenylbutyrate, and taurursodiol for the treatment of amyotrophic lateral sclerosis, or ALS. On the question, "Do the data from the single randomized, controlled trial and the open-label extension study establish a conclusion that sodium phenylbutyrate / taurursodiol is effective in the treatment of patients with amyotrophic lateral sclerosis, or ALS, the PCNSDAC voted 4 yes and 6 no. "We remain confident in the data from the Phase 2 CENTAUR trial and the potential benefits of AMX0035 as a treatment option for people living with ALS," said Jamie Timmons, Head of Scientific Communications of Amylyx. "We are motivated by the hundreds of people impacted by this devastating disease who shared their personal testimonies, both written and spoken, in conjunction with today's meeting. We are also encouraged by the expert ALS physicians who shared their clinical perspectives. Our application is under review by the FDA, and we remain committed to pursuing its approval given the pressing need for new treatments for ALS."

18:37 EDT Taseko Mines announces 40% increase in Gibraltal Mine reserves - Taseko Mines "announces a new 706 million ton proven and probable sulphide reserve for the Gibraltar Mine, a 40% increase as of December 31, 2021. The new reserve estimate allows for a significant extension of the mine life to 23 years with total recoverable metal of 3.0 billion pounds of copper and 53 million pounds of molybdenum."

18:14 EDT ViiV Healthcare announces FDA approval of Triumeq PD - ViiV Healthcare, the global specialist HIV company majority-owned by GlaxoSmithKline (GSK), with Pfizer (PFE) and Shionogi Limited as shareholders, has announced that the U.S. FDA has approved a new drug application for a dispersible tablet formulation of the fixed dose combination of abacavir, dolutegravir and lamivudine for the treatment of pediatric patients weighing 10kgs to less than 25 kgs with human immunodeficiency virus type 1. In addition, a supplemental new drug application has been approved for Triumeq tablet, lowering the minimum weight that a child with human immunodeficiency virus type 1 can be prescribed this medicine to 25kgs from 40kgs.

17:53 EDT Four Corners Property Trust acquires Express Oil Change property for $1.5M - Four Corners Property Trust announced the acquisition of an Express Oil Change property for $1.5M. The property is located in a highly trafficked corridor in Mississippi and is occupied under a triple net lease to the corporate entity with approximately eleven years of term remaining. The transaction was priced at a 6.3% capitalization rate, exclusive of transaction costs.

17:32 EDT Granite wins $20M road improvement contract in Arizona - Granite has been awarded a major road improvement project by the City of Chandler, Arizona. The approximately $20M award will be federally funded and managed by the city. It is the largest contract so far for Granite's newly established Phoenix Area office . The award is anticipated to be included in Granite's first quarter CAP. The project is expected to begin in May 2022 and projected completion is July 2023.

17:23 EDT ESAB to be added to S&P 400 at open on 4/5 - Colfax (CFX) is spinning off ESAB (ESAB) in a transaction expected to be completed on April 5. Post spin-off, Colfax will be renamed Enovis (ENOV) and will remain in the S&P MidCap 400.

17:04 EDT Cryoport returns to full production at New Prague plant, raises revenue impact - Cryoport's New Prague facility has returned to full production after a fire occurred in a portion of the MVE Biological Solutions manufacturing facility located in New Prague, Minnesota on January 25, causing production to be temporarily curtailed. The New Prague facility manufactures aluminum dewars and is one of MVE Biological Solutions' three global manufacturing facilities. Cryoport previously announced it would resume production at the New Prague facility during the week of February 14th and ramp up to full production during Q1. The company also guided to a revenue impact from the fire of $4M-$5; limited to Q1. However, a number of unexpected challenges resulting from the fire caused the recommissioning and validation of production to progress more slowly than had been previously anticipated. As a result, Cryoport now expects a revenue impact from the fire of $9.0M-$9.5M which will remain limited to Q1. The company expects its insurance to cover the majority of the costs to restore and re-open the facility, as well as related business interruption losses.

17:01 EDT mCloud Technologies, Carbon Royalty enter deal to fund AssetCare EV Solutions - mCloud Technologies "announced it had signed an agreement on March 28, 2022 with Carbon Royalty Corp to proceed with closing and funding the first 30 AssetCare solutions to optimize Electric Vehicle charging efficiency at auto dealerships in the states of New York and California."

17:00 EDT Occidental Petroleum CEO Hollub acquires 14,191 common shares - In a regulatory filing, Occidental president and CEO Vicki Hollub disclosed the purchase of 14,191 common shares of the company on March 28, 2022 at a price of $56.24 per share.

16:47 EDT Howard Hughes sells equity stake in 110 North Wacker Drive for $210M - The Howard Hughes Corporation has announced the sale of its equity interest in 110 North Wacker Drive, a 55-story, 1.5-million-square-foot Class-A office tower in Chicago, to Callahan Capital Partners and Oak Hill Advisors. The transaction involves the sale of 100% of the equity interest in 110 N. Wacker Development, LLC, by a limited liability company that HHC owns 90% of, for $210M, in the aggregate. Based on this sales price, the implied value of the office tower is more than $1B, which would be the second-highest valuation of all time for a Chicago office property, and the highest valuation for an office property in Chicago since the sale of the Willis Tower in 2015. Co-developed by The Howard Hughes Corporation and Riverside Investment and Development Company, the 110 North Wacker Drive tower provided a huge value creation opportunity for HHC, who invested net cash into the building of $13M and realized net proceeds of approximately $169M over the four-year development timeline. "The sale of 110 North Wacker Drive is a meaningful step in the execution HHC's non-core asset dispositions," said David R. O'Reilly, Chief Executive Officer of The Howard Hughes Corporation. "The sale generates significant net proceeds, which we will reinvest back into new developments and use to repurchase shares as part of our stock buyback program."

16:40 EDT Artemis Strategic Investment to combine with gameTech operator Novibet - Artemis Strategic Investment and Logflex MT DBA "Novibet", a technology-enabled operator, entered into a definitive agreement for a business combination, whereby Artemis will merge into a new wholly-owned subsidiary of Novibet in a transaction based on Novibet's pre-transaction enterprise valuation of $625M. Following completion of the transaction, Novibet's ordinary shares will be listed on Nasdaq. Artemis founders and existing Novibet stakeholders will hold approximately 75% of the combined company at close. Founded in 2010, Novibet currently operates iGaming and online sports betting actively across four regulated European markets: Greece, Ireland, Italy, and Malta. Over the last four years, Novibet has grown gross gaming revenue at a compound annual rate of approximately 107% for 2021, with EBITDA during this period increasing at a compound annual rate of approximately 182%. Initial execution against these multi-year growth initiatives is expected to help drive growth in full year 2023 projected net gaming revenue to approximately $200M and EBITDA to approximately $37M. Pro forma for the transaction, the implied enterprise valuation is approximately $696M, assuming no redemptions from Artemis stockholders. Novibet's shareholder will roll at least 92% of their equity into ordinary shares of the combined company. Rodolfo Odoni, current owner of Novibet will be named Chairman of Novibet; George Athanasopoulos, CEO of Novibet, to remain CEO. Artemis will appoint two representatives to the Novibet Board of Directors. Novibet has more than 350,000 annual unique active customers in 2021 and expects to launch iGaming and OSB operations in Canada through its own license, beginning with Ontario in Q4, and to launch iGaming and OSB operations in Mexico through a partnership with a land-based operator beginning in Q3. The transaction has been unanimously approved by the Boards of Directors of both companies and is expected to close in the second half of 2022, subject to approval by Artemis' shareholders and other customary closing conditions.

16:33 EDT Idex Corp. acquiring KZValve - Idex Corporation has entered into a definitive agreement to acquire KZ CO. - KZValve -, a manufacturer of electric valves and controllers used primarily in the agriculture market. Founded in 1976, KZValve creates and manufactures a variety of precision farming components including waterproof motorized valves, manifolds, controllers and other accessories. Besides agriculture, the company serves other segments including water filtration, de-icing and anti-icing, and emergency fire services. KZValve employs about 100 people. KZValve will become part of the agriculture group within IDEX's Fluid & Metering Technologies segment. Headquartered in Greenwood, Nebraska, KZValve is expected to have sales of approximately $28.0M in FY22. The transaction is expected to close in Q2, subject to regulatory approvals and customary closing conditions.

16:31 EDT Stealth Biotherapeutics reports new SBT-272 trial data - Stealth BioTherapeutics Corp announced the presentation of new SBT-272 preclinical data at the Mitochondrial Biochemistry in Health and Disease Symposium in Breckenridge, CO and dosing of the first subject in its Phase 1 clinical trial of SBT-272. The new data demonstrated behavioral and metabolic improvements with SBT-272 in a mouse model of Huntington's disease. In the study, mice were treated for up to 8 weeks with daily SBT-272 and displayed significantly improved motor function compared to vehicle-treated mice. SBT-272-treated mice also showed improved metabolism in multiple brain regions of the diseased animals, assessed in vivo using PET imaging. The Phase 1 clinical trial is a double-blind, placebo controlled safety study enrolling up to 64 healthy subjects across multiple cohorts. SBT-272 is being administered via subcutaneous injection. As a primary objective, the study will evaluate safety and tolerability of single and multiple ascending doses of SBT-272. Secondary objectives include an analysis of the pharmacokinetic profile of SBT-272 and identification of the appropriate dose range for Phase 2 testing. "We see tremendous potential for SBT-272 across a spectrum of neurodegenerative diseases of mitochondrial dysfunction, with supportive preclinical data in amyotrophic lateral sclerosis, frontotemporal lobar dementia, Parkinson's and, with our new data, Huntington's disease," said Chief Executive Officer Reenie McCarthy. "It's exciting to progress this promising compound into the clinic as an important first clinical step toward initiating planned development efforts for patients affected by these devastating diseases."

16:27 EDT UiPath falls 23% to $22.30 after Q4 results and below-consensus revenue outlook

16:26 EDT Izea jumps 32% to $1.90 per share after Q4 results

16:25 EDT Artemis Strategic Investment Corp trading halted, news pending

16:22 EDT Northwest Pipe awarded steel pipe contract on Red River Valley project - Northwest Pipe has been selected by Garney Construction to manufacture engineered steel water transmission pipe for the latest segment of the Red River Valley Water Supply Project - RRVWSP - in central and eastern North Dakota, The Garrison Diversion Conservancy District and Lake Agassiz Water Authority are co-sponsors of the RRVWSP, which will create a buried pipeline to carry water from the Missouri River near Washburn, ND, along Highway 200 to the Sheyenne River, above Lake Ashtabula. The pipe, which is being manufactured at the Saginaw, TX facility, will start being delivered to the job site this summer. In addition, the company is also supplying PermalokO steel casing pipe for the intake on the Missouri River.

16:20 EDT Clarus Therapeutics says continuing to explore strategic alternatives - The company said, "Our cash and cash equivalents as of December 31, 2021 will fund our current operating plan into approximately April 2022. Accordingly, we continue to explore strategic alternatives for the purpose of maximizing stockholder value and expect to devote significant efforts to raise capital, restructure our indebtedness and identify and evaluate potential strategic alternatives. There can be no assurance that these efforts will be successful, and our board of directors is assessing appropriate alternatives available to Clarus. Any failure in these efforts could force us to delay, limit or terminate our operations, make reductions in our workforce, discontinue our commercialization efforts for JATENZO as well as other development programs, liquidate all or a portion of our assets or pursue other strategic alternatives, and/or seek protection under the provisions of the U.S. Bankruptcy Code."

16:16 EDT Masimo reports preliminary Q1 product revenue $285M-$315M - Masimo expects its product revenue for the first quarter of 2022 will range from $285 million to $315 million. Shortages of critical components in combination with other supply chain issues, including freight carrier delays, have led to lower than expected sales in the first quarter.

16:11 EDT Marathon Digital CFO Sim Salzman to switch roles, Hugh Gallagher to succeed - Marathon Digital has appointed Hugh Gallagher to the position of chief financial officer effective March 31. In conjunction with this addition to Marathon's leadership team, Sim Salzman, the company's current chief financial officer, will be transitioning to the role of chief accounting officer, also effective March 31.Prior to joining Marathon, Gallagher was the chief strategy officer at Global LPG.

16:09 EDT UiPath names Chris Weber as Chief Business Officer - UiPath (PATH) announced that Chris Weber is joining the Company's executive team to become its first-ever Chief Business Officer effective April 4, 2022. A former Microsoft executive that brings more than 25 years of enterprise software experience, Weber will be responsible for leading global go-to-market strategy and execution at UiPath, and will guide worldwide sales, services, and other go-to-market operations including its partner organization. Weber joins UiPath most recently from Microsoft (MSFT), where he served as Corporate Vice President of Microsoft's Corporate and Small and Medium-Sized Business commercial team and led Digital Sales across the commercial business.

16:07 EDT Franklin Covey sees FY22 sees FY22 adjusted EBITDA $38M-$39M - The company said: "Based on the Company's strong performance in the first and second quarters of fiscal 2022, and anticipated results for the remainder of the current fiscal year, the Company is pleased to increase its guidance for fiscal 2022 and now expects Adjusted EBITDA to total between $38.0 million and $39.0 million. The middle of this range reflects 37.5% growth in Adjusted EBITDA compared with the $28.0 million achieved in fiscal 2021. The Company remains confident the strength of the All Access Pass and Leader in Me membership subscriptions, which have driven Franklin Covey's growth trajectory across recent years, and which have remained strong during the pandemic, will drive continued growth in the second half of fiscal 2022 and subsequent years. However, the Company's growth trajectory in the third and fourth quarters is expected to be impacted by comparisons to prior year periods which were less impacted by the COVID-19 pandemic, and by planned investments in the second half of fiscal 2022 for long-term growth. These investments include the costs associated with: 1) hiring new client partners to position the Company for sales growth in future periods; 2) additional investments in content and delivery platform development; and 3) other growth investments, including sales support personnel. The first and second quarters of fiscal 2021 included the early stages of the COVID-19 pandemic in the United States, Canada, and many other countries throughout the world, which had a significantly adverse impact on the Company's financial results during those quarters. Comparisons of the first and second quarters of fiscal 2022 with the same quarters of fiscal 2021 reflect those conditions and the strengthening of Company operations over the course of the pandemic, which has produced large variances in the current period analyses. As recovery from the COVID-19 pandemic progressed through prior-year periods in the third and fourth quarters of fiscal 2021, the Company does not expect the large variances to prior year results to continue in the remainder of fiscal 2022."

16:04 EDT F45 Training names Brian Killingsworth as Chief Marketing Officer - F45 Training announced the appointment of Brian Killingsworth as Chief Marketing Officer. Joining the executive leadership team, Killingsworth will report to Adam Gilchrist, President, CEO & Chairman. Killingsworth will lead F45's marketing strategy and, with his extensive experience in the sports industry, lead the Company's branding, advertising and efforts to market to existing and new customers.

14:44 EDT Apple says changes show commitment to legal obligations in Netherlands - Apple stated in an update posted to its site for developers: "Since February of this year, developers of dating apps on the App Store in the Netherlands have been able to use the StoreKit External Purchase Entitlement or the StoreKit External Purchase Link Entitlement to enable the capability to sell services through a payment system other than Apple's in-app purchase system. Apple established these entitlements as part of our plan to comply with a recent Netherlands Authority for Consumers and Markets order. Today we've introduced changes to these entitlements... Developers of dating apps who want to continue using Apple's in-app purchase system - which we believe is the safest and most secure way for users to purchase digital goods and services - may do so and no further action is needed. As we have previously said, we disagree with the ACM's original order and are appealing it. In the meantime, the changes we've made today demonstrate Apple's ongoing commitment to fulfill its legal obligations in the Netherlands." Reference Link

14:05 EDT Akebia trading resumes

13:54 EDT CoreCard drops after report says Apple looks to bring finance services in-house - Shares of CoreCard (CCRD) are down about 12% in afternoon trading after Bloomberg's Mark Gurman reported, citing sources, that Apple is working on a project, dubbed "Breakout," that would reduce its reliance on outside fintech partners over time. The company's Apple Card currently uses CoreCard as its core processor and the card relies on Goldman Sachs (GS) for other components like lending and credit checks, Gurman's report noted.

13:36 EDT Akebia receives complete response letter from FDA for vadadustat NDA - Akebia Therapeutics announced that the U.S. Food and Drug Administration has issued a complete response letter, or CRL, to Akebia's New Drug Application, or NDA, for vadadustat, an investigational oral hypoxia-inducible factor prolyl hydroxylase inhibitor under review for the treatment of anemia due to chronic kidney disease, or CKD. The FDA issues a CRL to indicate that the review cycle for an application is complete and that the application is not ready for approval in its present form. The FDA concluded that the data in the NDA do not support a favorable benefit-risk assessment of vadadustat for dialysis and non-dialysis patients. The FDA expressed safety concerns noting failure to meet non-inferiority in MACE in the non-dialysis patient population, the increased risk of thromboembolic events, driven by vascular access thrombosis in dialysis patients, and the risk of drug-induced liver injury. The CRL stated that Akebia could explore ways to potentially demonstrate a favorable benefit-risk assessment through new clinical trials. Akebia will discuss the details of the CRL with its collaboration partners and request a meeting with the FDA. "We are extremely disappointed to receive a CRL for vadadustat, a therapy that has the potential to help patients with anemia due to CKD. We continue to believe the data are supportive of a positive benefit-risk assessment of vadadustat for patients with anemia due to CKD, particularly in dialysis patients. Despite this setback, we continue to work toward our purpose to better the lives of people impacted by kidney disease," said John Butler, CEO of Akebia. Akebia will host a conference call Wednesday, March 30 at 6:00 p.m. Eastern Time to discuss the CRL and next steps, the company noted.

13:10 EDT Yellowstone Acquisition Corp trading resumes

13:03 EDT Roblox announces partnership for first official virtual 'Grammy Week' experience - The Recording Academy announced a partnership with Roblox for a "Grammy Week" experience that will be held virtually from March 30 through April 3. "The activations, in partnership with Mastercard, feature artist avatar meet & greets, chats, mini games, prizes, and a performance by two-time GRAMMY nominee, five-time Latin GRAMMY winner and Latin recording artist Camilo... The partnership marks the Academy's debut into the Metaverse and is Roblox's first brand-funded music activation," the Academy and company announced.

12:48 EDT Anixa Biosciences initiates ovarian cancer CAR-T Phase 1 trial - Anixa Biosciences announced the initiation of a Phase 1 trial evaluating its chimeric antigen receptor T-cell therapy in ovarian cancer. The CAR-T approach used for Anixa's therapy is known as chimeric endocrine receptor T-cell since the target of the engineered T-cells is an endocrine receptor. The Phase 1 trial at Moffitt Cancer Center will evaluate the safety and efficacy of Anixa's therapy in patients with ovarian cancer. Anixa holds a worldwide license for the technology, which was developed at the Wistar Institute.

12:43 EDT Casi Pharmaceuticals added to SEC provisional list of companies under HFCAA - Casi Pharmaceuticals was added to the Securities and Exchange Commission's provisional list of companies identified under the Holding Foreign Companies Accountable Act. The statute requires the SEC to identify public companies "that have retained a registered public accounting firm to issue an audit report where the firm has a branch or office that: (1) is located in a foreign jurisdiction, and (2) the Public Company Accounting Oversight Board has determined that it is unable to inspect or investigate completely because of a position taken by an authority in the foreign jurisdiction." Reference Link

12:42 EDT Baidu added to SEC provisional list of companies under HFCAA - Baidu was added to the Securities and Exchange Commission's provisional list of companies identified under the Holding Foreign Companies Accountable Act. The statute requires the SEC to identify public companies "that have retained a registered public accounting firm to issue an audit report where the firm has a branch or office that: (1) is located in a foreign jurisdiction, and (2) the Public Company Accounting Oversight Board has determined that it is unable to inspect or investigate completely because of a position taken by an authority in the foreign jurisdiction." Reference Link

12:39 EDT Amylyx trading halted amid FDA Advisory Committee meeting on AMX0035 - Earlier, Amylyx Pharmaceuticals announced that Nasdaq has halted trading of the company's common stock. The U.S. Food and Drug Administration's Peripheral and Central Nervous System Drugs Advisory Committee is meeting today to review the New Drug Application for AMX0035 for the treatment of amyotrophic lateral sclerosis, or ALS. The Advisory Committee meeting is scheduled for 10:00 a.m. ET and the briefing materials can be found on the FDA website, the company noted. The Prescription Drug User Fee Act, or PDUFA, target action date for the AMX0035 NDA is June 29, Amylyx stated.

12:33 EDT Globant trading resumes

12:31 EDT Comtech appoints Maria Hedden as COO - Comtech Telecommunications announced that it has hired Maria Hedden as its new COO. In her new role, Hedden will be responsible for leading and implementing operational excellence across Comtech, such as improving production capabilities and on-time delivery schedules, through retaining and scaling engineering and operations teams to improve margins and to keep pace with expected business growth, Comtech said in a statement.

12:17 EDT Athira Pharma says Richard Kayne rejected 'attempts to find common ground' - Athira Pharma issued the following statement in response to the release from Richard Kayne: "Athira's board and leadership team are focused on doing what is right for the company, our shareholders and patients. Athira's highest priority is advancing fosgonimeton through clinical trials and securing regulatory approval for the treatment of Alzheimer's disease, which impacts as many as 35 million people worldwide. Athira is executing well against that objective and delivering on our target milestones. We are poised to report top line results from the Phase 2 ACT-AD study in the second quarter, which we anticipate will validate the Phase 1b compelling P300 latency results and provide insight into the activity and safety of fosgonimeton. We are also making strong progress advancing our LIFT-AD and SHAPE clinical trials and pipeline. The board of directors is confident Athira has the right strategy and the right team to lead the company through this pivotal chapter...Members of our board have spoken with Mr. Kayne numerous times, and especially over the last several weeks. These conversations have focused on our desire to find a collaborative path forward that would allow us to devote our focus and resources to clinical trials and advancing fosgonimeton, which we believe is clearly in the best interests of Athira and our shareholders. Mr. Kayne has rejected our attempts to find common ground. Mr. Kayne has pushed Athira to resume a formal relationship with his current business partner and the company's former CEO, Dr. Leen Kawas, who resigned as an executive and stepped down from the board in October 2021. This occurred after an investigation led by an independent board committee found that she altered images in her 2011 doctoral dissertation and in at least four research papers that she co-authored while a graduate student at Washington State University. The board believes that ending Dr. Kawas's relationship with Athira was and remains in the best interests of Athira and our shareholders."

12:00 EDT RH falls -13.0% - RH is down -13.0%, or -$50.09 to $335.60.

12:00 EDT Starry falls -14.1% - Starry is down -14.1%, or -$1.30 to $7.91.

12:00 EDT Lithium Americas rises 14.2% - Lithium Americas is up 14.2%, or $4.69 to $37.64.

11:59 EDT CDC no longer warning about Covid risk on cruise ships, CNBC's Mody says - CNBC's Seema Mody said via Twitter: "CDC says it is no longer warning travelers about the risk of COVID on board cruise ships...follows a tumultuous two years where U.S. health officials banned sailing for 15 months and restricted sailings. Full circle moment." Reference Link

11:31 EDT Florida announces $860M opioid settlement with CVS, Teva, Allergan - Florida Attorney General Ashley Moody announced the securement of $860M for opioid abatement from CVS Health (CVS), Teva Pharmaceuticals Industries (TEVA) and AbbVie's (ABBV) Allergan. CVS will now pay $484M to Florida, Teva will pay nearly $195M, and Allergan will pay more than $134M to resolve claims relating to the companies' role in the opioid epidemic. Teva will also provide $84M worth of its generic Narcan nasal spray to the State. Additionally, Attorney General Moody is announcing that the Endo Health Solutions (ENDP) settlement is now finalized, with every litigating city and county in Florida-more than 90 in total-participating. The remaining defendant, Walgreens (WBA), is set for a jury trial beginning on April 5, Moody points out. Opening statements are likely to occur on or about April 8. Reference Link

11:12 EDT Figs adds A.G. Lafley, Kenneth Lin and Jeffrey Wilke to board - Earlier, Figs announced that A.G. Lafley, Kenneth Lin and Jeffrey Wilke have been appointed to the company's board of directors, effective April 1. Each will join the board as an independent director, and Ken and Jeff will also be appointed to the board's audit committee, the company noted. "A.G. Lafley is a seasoned public company CEO who spent almost 40 years at The Procter & Gamble Company, one of the largest consumer goods companies in the world... Ken Lin is a successful founder and technology leader with a deep understanding of how to engage with consumers in the digital age. Since March 2007, Ken has been the CEO of Credit Karma, the consumer finance company that he founded... Jeff Wilke is one of the world's foremost operations leaders, with a deep understanding of the direct-to-consumer, supply chain, logistics and technology spaces. Jeff joined Amazon in 1999 to lead operations and he ultimately spent more than 20 years on its senior management team," the company noted in announcing its director additions.

11:02 EDT American Electric names Sandy Nessing as VP, chief sustainability officer - American Electric Power has promoted Sandy Nessing to vice president and chief sustainability officer, effective April 1. Nessing currently is the managing director of Corporate Sustainability and is responsible for leading the company's sustainability and environmental, social and governance strategy, corporate stakeholder engagement, and annual sustainability and ESG performance reporting and risk monitoring. She will continue to report to David Feinberg, executive vice president, general counsel and secretary.

11:01 EDT Queen's Gambit receives shareholder approval for Swvl combination - Queen's Gambit Growth Capital announced that its shareholders voted to approve the previously announced business combination with Swvl and all other proposals presented at Queen's Gambit's extraordinary general meeting of shareholders on March 30, 2022. Queen's Gambit plans to file the results of the Shareholders' Meeting, as tabulated by an independent inspector of elections, on a Form 8-K with the U.S. Securities and Exchange Commission. Subject to the satisfaction or waiver of the other customary closing conditions, the business combination is expected to close on March 31, 2022. Following closing, the combined company will change its name to "Swvl Holdings Corp." Swvl Holdings Corp's Class A ordinary shares and Swvl Holding Corp's warrants are expected to commence trading on NASDAQ under the ticker symbols "GMBT" and "GMBTW", respectively, for one day on March 31, 2022. The next day, on April 1, 2022, Swvl Holdings Corp's Class A ordinary shares and Swvl Holding Corp's warrants are expected to commence trading on NASDAQ under the ticker symbols "SWVL" and "SWVLW", respectively.

10:36 EDT RGC Resources announces $4M investment from T. Rowe Price - RGC Resources (RGCO) closed a $4M common stock investment by funds and accounts advised by T. Rowe Price Investment Management (TROW). T. Rowe Price's investment follows the $23M of investments announced by Resources on March 28, 2022.

10:16 EDT Globant trading halted, news pending

10:01 EDT MetroRio deploys Motorola Solutions' body-worn cameras - Brazil's MetroRio has equipped its security officers with VB400 body-worn cameras from Motorola Solutions, as commuter and tourist rail travel gradually returns to normal levels after the pandemic. With an average of 510,000 passengers traveling across a network of 41 stations each day, the rail operator chose the body-worn video solution to enhance efficiency and increase passenger safety while confirming the security protocols followed by the personnel are effective. The VB400 cameras will provide the transit operator with greater visibility across its 58 kilometer rail network at all times. MetroRio's security team will wear the cameras inside metro stations and during onboard patrols, enabling events to be recorded in both audio and video capturing events in real-time whenever needed.

10:00 EDT RH falls -10.0% - RH is down -10.0%, or -$38.65 to $347.04.

10:00 EDT Nine Energy Service rises 10.8% - Nine Energy Service is up 10.8%, or 36c to $3.68.

10:00 EDT KE Holdings rises 11.4% - KE Holdings is up 11.4%, or $1.46 to $14.28.

09:50 EDT Revelation Biosciences Inc trading resumes

09:47 EDT AerCap falls -7.9% - AerCap is down -7.9%, or -$4.46 to $51.71.

09:47 EDT Kore Group rises 9.6% - Kore Group is up 9.6%, or 52c to $5.95.

09:47 EDT Nine Energy Service rises 19.6% - Nine Energy Service is up 19.6%, or 65c to $3.97.

09:38 EDT Nevada reports February statewide gaming win up 44.1% to $1.11B - Reports February Las Vegas Strip gaming win up 71.94% versus last year to $599.13M. Publicly traded companies in the gambling space include Boyd Gaming (BYD), Caesars (CZR), Churchill Downs (CHDN), DraftKings (DKNG), Flutter Entertainment (PDYPY), Gan Limited (GAN), Las Vegas Sands (LVS), MGM Resorts (MGM), Penn National (PENN), William Hill (WIMHY) and Wynn Resorts (WYNN).

09:31 EDT Cinedigm CEO Chris McGurk outlines key growth initiatives - The CEO said,"It's been several months since my last letter to shareholders and the world has certainly changed over that time. Obviously, geopolitical factors and market sentiments have made it a very tough period for many in the capital markets and certainly for Cinedigm shareholders. Therefore, I thought it was very important to reach out to our shareholders, closely following our most significant acquisition yet, to reaffirm that Cinedigm, by every measure, remains in the strongest position it has ever been in, with tremendous growth prospects. As you know, we have registered four straight record quarters of triple-digit streaming revenue growth and have generated positive net income over the first three quarters of Fiscal 2022. We have continued that momentum over the last two months with continued record streaming revenues in January and February. Given this success, we should easily exceed $50 million in consolidated revenues for the full fiscal year ending March 31, 2022, which represents an over 60% increase above the prior year. We also project that we will easily more than double our full year streaming revenues versus last year. Finally, the Company has a strong balance sheet with zero debt and adequate cash on hand. We are also very pleased to begin our new fiscal year having closed the accretive DMR transaction two days ago. Not only does DMR add 10 new streaming channels and 7,500 films and TV series to our asset base plus a projected $10 million in revenues and $3 million in adjusted EBITDA over the next 12 months, but it also drives Cinedigm to an expanded business scale that will support the launch of four new growth initiatives that we expect will generate over $28 million in incremental annual revenues when fully rolled out. We were very deliberate in closing the DMR acquisition...Therefore, immediately taking advantage of Cinedigm's expanded scale, I would like to announce four key new and interrelated initiatives that we project will generate over $28 million in aggregate annual revenues at steady state in the mid-term. All four of these initiatives require minimal investment in additional overhead and working capital while generating very high expected returns, as we will be building them almost entirely from our existing asset base. Cineverse - Over the last year, we have been hinting at a new streaming service that will showcase the best of Cinedigm's films, series, channel brands, technology and social reach. Today, we are excited to announce that this service has a name: Cineverse. Cineverse will be your ticket to a world of entertainment delights, thrilling filmmaker discoveries, and more. In a world where algorithms steer viewers towards the predictable, Cineverse will buck that trend with a focus not only on passionate curation, but also by leveraging our Matchpoint technology to provide next generation content recommendations based on real-time feedback from the viewer. From artfully entertaining American indies to the boldest in global film and television, emerging voices, and non-fiction storytelling, our library of world-class content will reward the curious and adventurous. Cinedigm Ad Solutions - Over the last three years, Cinedigm's streaming business has grown from a subscription-centric business model to one with a scale, multi-faceted advertising business focused on highly engaged, addressable enthusiast audiences. Cinedigm has a unique cross-platform ad footprint, with a massive Connected TV, podcast & audio, display, and social footprint. With the acquisition of DMR, this footprint is even larger, totaling 40 million viewers across 30 channels, millions of podcast fans, and almost 20 million social media followers. Given the dramatic rise in advertisers and agencies intent on reaching this valuable audience, we are launching Cinedigm Ad Solutions, an ad network to enable advertisers to reach highly engaged, diverse enthusiast fan bases in cohesive, multi-platform campaigns. Not only will CAS enable Cinedigm to more effectively monetize its own inventory, Cinedigm will also bring other complementary, scale enthusiast audiences into our network. Between our acquisition of Bloody Disgusting and DMR, our team has over fifty years of experience building and scaling direct ad businesses, and we are now providing them the resources to build a substantial scale business. Cinedigm Podcast Network: Cinedigm's streaming business has always been about engaging fans in the medium of their choice - audio, video, digital comics, text, and more. With last year's acquisition of Bloody Disgusting, we entered the world of Audio programming. Today, with 11 successful podcasts and growing with millions of monthly listeners and a seven-figure revenue base, we are expanding the successful genre-focused podcasting efforts with the launch of Cinedigm Podcast Network. Our focus will be simple: we will continue to offer compelling podcasts that appeal to segments where we already are highly successful, like fandom, world & independent cinema, faith and family. Our goal is to triple our in-house produced shows over the next three years, as well as dramatically expand ad sales and distribution for third-party shows that fit our content verticals. Not only will this business be a substantial source of revenue, but it will also provide substantial intellectual property that can be expanded into new films and series for the broader content business. Matchpoint Blueprint 2.0 - Cinedigm has continued to invest in building a world-class engineering team in India. This has allowed the Company to expand and refine the capabilities of our Matchpoint application framework for direct-to-consumer apps and services. We are leveraging Artificial Intelligence and Machine Learning as much as possible to bring a next-generation user experience to our channels, along with providing a robust product differentiation not seen in other services. We aim to take a leadership role in defining how a streaming service can provide an unrivaled and exceptional user experience. Besides these initiatives, all of which we will announce in much more detail within the next few months, we have a set a goal to become sustainably cash flow positive by the end of this upcoming Fiscal Year 2023. Already, we are way ahead of most of our competitors by having a portfolio of streaming channels and revenue sources that enable us to minimize risk while taking advantage of every segment of the high-growth streaming business with zero debt on the balance sheet and positive net income year to date. Demonstrating that we can be sustainably cash flow positive will be another key indicator of the success of our strategy and how different we are from our streaming competitors. So, while the capital markets have been extraordinarily challenging for the last few months, Cinedigm remains in the strongest position ever to continue to build an important, lasting and high-growth streaming, content and technology company that will reward shareholders who have a long-term perspective with significant growth in value. Through two years of intense effort by the Cinedigm team, all the elements needed for even more dramatic growth and business success are now in place. With the DMR acquisition closed and these four new business initiatives rolling out, the team is more confident than ever that our business momentum will continue for years to come as we build toward our goal of becoming a $150 million revenue business in two to four years."

09:28 EDT Xinyuan Real Estate announces strategic cooperation agreement with Wanda Group - Xinyuan Real Estate announced that the company and Wanda Group held a strategic cooperation conference in Beijing on March 28. Jianlin Wang, Chairman of Wanda Group, and Yong Zhang, Chairman of Xinyuan Real Estate, were in attendance. During the conference, Xinyuan and Wanda Group signed a strategic cooperation agreement. Pursuant to the Agreement, the parties will establish comprehensive and in-depth business cooperation in business and asset management, industrial real estate, and research and development.

09:26 EDT Endra strengthens TAEUS IP protection with patent issuances in China - ENDRA Life Sciences announces that the Chinese National Intellectual Property Administration has issued ENDRA two new patents, Chinese Patent No. ZL 2019 8 00400927, titled "Method and System for Determining Fractional Fat Content of Tissue," and Chinese Patent No. ZL 2019 8 00870250 titled "Radio Frequency Applicator and Thermoacoustic Imaging System Employing the Same". "Having recently announced our first research partnership in China with the renowned Shanghai General Hospital, we are keen to bolster our intellectual property protection in Asia's largest healthcare market. We now have 11 patents issued in China supporting our strategy to develop thermoacoustic imaging systems and broadening the application for our proprietary TAEUS technology in areas with unmet clinical needs," stated ENDRA's Chairman and Chief Executive Officer Francois Michelon. "We continue to enhance our intellectual property portfolio to protect our technology in priority global markets. Our portfolio currently stands at 89 assets, which we define as patents issued, filed or in preparation." The '927 patent covers a method and system for determining fractional fat content of tissue that takes into consideration the speed of sound in that tissue. This patent builds upon ENDRA's growing number of issued patents in the area of tissue fat quantification. Conventional ultrasound image formation methodologies assume a single speed of sound, while the '927 patent leverages TAEUS' inherent sensitivity to fractional fat differences in tissue to estimate the actual speed of sound in tissue, and thereby improves the accuracy of TAEUS fat quantification methodologies. The patent also describes a calibration methodology for fractional fat measurements. The '927 patent is linked to its parent, U.S. patent No. 10258277B2. The '250 patent provides more robust intellectual property protection for the TAEUS platform related to its disruptive scanning approach. It covers a radio frequency applicator device and system for providing reliable RF energy to a target area of tissue. More specifically, the '250 patent structurally defines ENDRA's innovative solution to providing targeted RF energy to tissue regions for applications, such as fat quantification of a patient's liver. The '250 patent is linked to its parent, U.S. patent No. 10682059B1.

09:20 EDT Qualigen Therapeutics engages TD2 as CRO for QN-302 preclinical development - Qualigen Therapeutics announces it has appointed the renowned contract research organization Translational Drug Development to lead the preclinical development of lead drug candidate QN-302. Qualigen is initially investigating QN-302 for the potential treatment of pancreatic ductal adenocarcinoma (PDAC), which represents the vast majority of pancreatic cancers. QN-302 is Qualigen's genomic quadruplex-selective transcription inhibitor platform being developed as a potential treatment for PDAC, in addition to other tumors of high unmet clinical need. PDAC is one of the world's most lethal cancers, and the fourth-leading cause of cancer-related death in the United States. Each year, an estimated 460,000 people globally-and 60,000 in the United States-are diagnosed with PDAC, and it annually causes approximately 430,000 deaths worldwide and 48,000 in the United States. Qualigen believes that QN-302 may ultimately be eligible to obtain Orphan Drug Designation, with potential for key regulatory advantages.

09:18 EDT Zealand Pharma announces restructuring to pursue strategic partnerships - Following a review of all business operations, Zealand plans to maximize the value of V-Go and Zegalogue through strategic partnerships and will restructure its commercial organization in the United States while ensuring continuity of services by maintaining patient, physician, and payor support for V-Go and Zegalogue. Zealand will also seek commercial partnership opportunities for its late-stage clinical pipeline programs as it looks to further leverage its peptide platform though strategic collaborations. With the restructuring, the US workforce will be reduced 90% by Q3 of this year with additional cost reductions implemented in Denmark. "I realize that these changes impact employees in our organization and we are grateful to all our colleagues for their dedication and all they have done to improve the lives of patients," said Adam Steensberg, President and Chief Executive Officer of Zealand Pharma. "We have made the decision to restructure because we believe that seeking commercial partnerships will generate more value for the company and shareholders as we transform the company into a more focused and cost-effective organization. By improving our operational efficiency and targeting business development efforts, we will be in position to fully leverage the value of our most advanced assets and develop new peptide-based therapies. We have a strong R&D pipeline with Phase III readouts this year for dasiglucagon in CHI and, glepaglutide in SBS in the second and third quarters respectively, and Phase I data for our Amylin analogue targeting obesity later this year."

09:15 EDT Attollo Engineering selects LightPath's freeform optics for LiDAR products - Attollo Engineering announced a collaboration with LightPath Technologies for the design and supply of innovative freeform optical components for use in Attollo's LiDAR products.

09:13 EDT Cardinal Health plans to build new medical distribution center in Ohio - Cardinal Health announced plans to build a 574,670 square foot medical distribution center in the Columbus, Ohio area. "The new building will integrate automation and technology to work alongside Cardinal Health employees; improve safety, service and quality; deliver operational efficiencies; and better support fluctuations in volume and labor to provide customers with a predictable and stable customer experience. The new Columbus facility will replace Cardinal Health's current 235,000 square foot facility in nearby Obetz, Ohio. The larger warehouse footprint and operations can accommodate a full transition of existing employees, and will create new job opportunities for the Ohio Valley market. In partnership with Duke Realty, a leading owner, developer, and manager of logistics and industrial properties, along with its joint venture partners Columbus Regional Airport Authority and Capitol Square, Cardinal Health anticipates the new facility to be fully operational by late 2022 or early 2023," the company stated.

09:12 EDT Safe Bulkers issues notice of redemption of Series C preferred shares - Safe Bulkers announced that it is calling for redemption of 1,492,554 of the outstanding 8.00% Series C Cumulative Redeemable Perpetual Preferred Shares, par value $0.01 per share, liquidation preference $25.00 per share. There are currently 2,297,504 issued and outstanding Series C Preferred Shares. The Series C Preferred Shares will be redeemed on April 29, 2022 at a redemption price of $25.00 per Series C Preferred Share plus all accumulated and unpaid dividends to, but excluding, the Redemption Date. From and after the Redemption Date, all distributions on the Series C Preferred Shares to be redeemed will cease to accumulate, such redeemed Series C Preferred Shares shall no longer be deemed outstanding, and all rights of the holders of such shares will terminate, except for the right to receive the Redemption Price, without interest thereon.

09:10 EDT Xerox Elem in strategic pact with Siemens for metal additive manufacturing - Xerox Elem (XRX) Additive Solutions announced a new collaboration effort with Siemens (SIEGY), "a company in manufacturing, aimed at strengthening the metal additive manufacturing capabilities of both businesses," said the statement. "This relationship highlights both companies' strong commitment to advancing the future of industrial additive manufacturing through innovation and partnerships. Siemens has purchased an ElemX metal 3D Printer, adding it to their fleet of additive machines inside their Charlotte Advanced Technology Collaboration Hub. The CATCH facility focuses on the industrialization of additive manufacturing, working with machine builders, material suppliers and end-customers. The ElemX leverages Xerox's liquid metal AM that uses cost-effective aluminum wire and incorporates the state-of-the-art Siemens SINUMERIK 840D sl control platform with its embedded digital twin technology to optimize the printing process. ElemX is a groundbreaking 3D metal printer that's simpler and safer to use and addresses supply chain resiliency for transportation, aerospace, defense and industrial manufacturing. The printer is easily deployed, requiring no special facility modifications for operation. Unlike many metal 3D printing technologies, the ElemX requires minimal post-processing and therefore provides a faster time-to-part. Siemens and Xerox have a mutual interest to explore technical developments in automation, software, materials and processes of the current and future ElemX systems," noted the release.

09:09 EDT TrueCar sees March total new vehicle industry sales 1,246,993 units, down 25% - TrueCar expects total new vehicle industry sales to reach 1,246,993 units in March, down 25% from a year ago and up 5% from February, when adjusted for the same number of selling days. This month's seasonally adjusted annualized rate for total light vehicle industry sales is an estimated 13.6M, down 23% from March 2021. Excluding fleet sales, TrueCar expects U.S. retail deliveries of new cars and light trucks to be 1,084,168 units, down 24% from a year ago and up 2% from February 2022.

09:08 EDT Nuvei announces partnership with XT.COM to facilitate onboarding of new users - Nuvei announced its partnership with XT.COM to facilitate the onboarding of new users. The collaboration between Nuvei, via its Simplex cryptocurrency on/off ramp solution, and XT.COM will make it easier for users to fund their accounts through convenient payment methods. The partnership between Nuvei and XT.COM is expected to introduce many new users to the XT.COM platform as they can fund their accounts with credit and debit cards, Apple Pay and bank transfers. The partnership with XT.COM expands Nuvei's reach into various regions across Asia, North America, and Europe. XT.COM partners include Btok in Asia and Tapatalk in North America and Europe. "We are delighted to support XT.COM with our global on-ramp solution," said Philip Fayer, Chair and CEO of Nuvei. "Our partnership will enable millions of new users to join the cryptocurrency ecosystem with a familiar eCommerce experience of using everyday payment methods."

09:07 EDT Hims & Hers, Carbon Health partner to expand care options - Hims & Hers and Carbon Health are partnering to access to a broader range of care options through the Hims & Hers platform. This collaboration advances Hims & Hers efforts to transform healthcare by adding another provider to its growing network of provider relationships, which now spans seven states and the District of Columbia, and giving customers broader access to care options. Licensed medical professionals on the Hims & Hers platform will provide patients with an option to connect to Carbon Health if they require additional primary care follow-up or evaluation, due to complex medical histories, symptoms, or risk factors for conditions for which Hims & Hers does not currently offer treatment.

09:07 EDT Wix.com partners with DoorDash to launch on-demand delivery for restaurants - Wix.com (WIX) announced a partnership with DoorDash Drive, DoorDash's (DASH) white-label fulfillment platform that powers direct delivery for any business, to integrate with Wix Restaurants. The integration provides restaurant owners using Wix Restaurants access to a delivery fleet. Businesses built on Wix Restaurants can now fulfill delivery orders made directly on their website, their Dine App and their fully Branded App through DoorDash Drive.

09:06 EDT Wix.com partners with DoorDash to launch on-demand delivery for restaurants - Wix.com announced a partnership with DoorDash Drive, DoorDash's white-label fulfillment platform that powers direct delivery for any business, to integrate with Wix Restaurants. The integration provides restaurant owners using Wix Restaurants access to a delivery fleet. Businesses built on Wix Restaurants can now fulfill delivery orders made directly on their website, their Dine App and their fully Branded App through DoorDash Drive.

09:05 EDT Wheels Up announces new strategic partnership with Tropic Ocean Airways - Wheel Up Experience announced a new strategic partnership and minority investment in Tropic Ocean Airways, the world's largest amphibious airline and leading provider of last-mile private charter and scheduled service in Florida, the Northeastern United States, the Bahamas, the Caribbean and beyond. The multiyear commercial agreement is the latest step by Wheels Up in its efforts to expand the addressable market for its product offerings and offer a seamless first- to last-mile travel solution for its members and customers. The agreement provides for the integration of Tropic Ocean's charter and certain scheduled by-the-seat services into Wheels Up's marketplace, and Wheels Up members and customers will be able to directly book and pay for travel on Tropic Ocean flights through their normal Wheels Up booking channels. The parties will initially focus on providing Wheels Up customers with greater accessibility to options within Tropic Ocean's current coverage area. Over time, the parties intend to expand to additional markets in the United States and the Caribbean. Together with the commercial agreement, Wheels Up also announced a minority capital investment in Tropic Ocean, a first for Wheels Up, to help fund the continued growth for Tropic Ocean and to support certain shared initiatives under the commercial agreement, including the introduction of new flight offerings that will be exclusive to Wheels Up customers.

09:04 EDT Philips announces commercial availability of Ambient Experience with FlexVision - Royal Philips announced commercial availability of the company's new solution for interventional rooms, Ambient Experience with FlexVision display, which will be showcased at the American College of Cardiology's 71st Annual Scientific Session & Expo, April 2-4, Washington, D.C., USA. Connecting to Philips Image Guided Therapy System - Azurion, it uses the system's large display to offer patients a calming multi-sensory experience while staff prepare them for their procedure, prior to the display being used for the actual intervention. It also allows patients and interventional team members to adapt the room's ambient lighting and sound to add to the overall feeling of calm, especially during the patient entry and preparation phases of procedures. Aimed at reducing patient anxiety during interventional procedures, Ambient Experience, leveraging FlexVision display, has the potential to improve the patient and staff experience, positively impact outcomes, and enhance workflows and productivity.

09:04 EDT Creatd announces plans to spin off web 3.0 assets - Creatd intends to spin off the OG Collection, the company's wholly-owned media library, and OG Gallery, its associated Web 3.0 platform business, into a new publicly-traded entity. Following the spin-off, Creatd intends to retain a minority interest in the new entity, with the remaining shares expected to be distributed to current and future shareholders. Following the spinoff, Creatd will continue to be able to leverage OG Gallery's technology for use across all of its four pillars, and in particular, its agency-oriented pillar, Creatd Partners. The Collection is not currently valued on the company's balance sheet based on purchase price accounting guidance, despite its physical assets having been independently appraised at $6M-$8M. The company is collaborating with Starchive, an platform for content storage, curation, and commerce both on and off the blockchain. In the future, Creatd expects to evolve the OG Gallery into a much broader ecosystem using blockchain. To advance the OG Collection curation effort, the company has assembled an Advisory Board. Currently, the company is in discussions concerning other transmedia opportunities including a book and screenplay, as well as a podcast inspired by the collection's files.

09:03 EDT BOS Better Online Solutions reports Q4 EPS 2c vs. 6c last year - Reports Q4 revenue $9.1M vs. $10.4M last year. Eyal Cohen, BOS's CEO, stated: "We have made positive progress in the year 2021, although revenues were roughly the same as in the year 2020: Gross profit margin improved to 19.6% in the year 2021 from 18.2% in the year 2020; Operating expenses decreased to $6.1 million in the year 2021 from $6.8 million in the year 2020; Financial expenses decreased to $105,000 in the year 2021 from $348,000 in the year 2020. As a result, net income for the year 2021 amounted to $451,000 as compared to a $960,000 net loss in the year 2020. On March 10, 2022, we announced that BOS' RFID division acquired the assets of Dagesh, which provides inventory counting services in Israel. In addition, on March 28, 2022, we announced that BOS' Supply Chain division received a $2.4 million order from an existing customer, for delivery this year. This advances us towards our financial targets for the year 2022, which are revenues over $35 million and net income to exceed $1 million."

09:02 EDT Fastly acquires Fanout, terms undisclosed - Fastly announced its acquisition of Fanout. The acquisition is part of Fastly's broader growth strategy to identify and deploy technologies and talent that increase performance, security and innovation for customers.

08:49 EDT Ambac Financial announces $20M share repurchase program - Ambac Financial Group announces that its Board of Directors has approved a share repurchase program, under which Ambac may opportunistically repurchase up to $20M of the Company's common shares at management's discretion over the period ending on March 31, 2024. Under the share repurchase program, shares may be repurchased from time to time in the open market or negotiated transactions at prevailing market rates, or by other means in accordance with federal securities laws. There is no guarantee as to the exact number or value of shares that will be repurchased by the company, and the company may discontinue repurchases at any time that management determines additional repurchases are not warranted. The timing and amount of share repurchases under the share repurchase program will depend on several factors, including the company's stock price performance, ongoing capital planning considerations, general market conditions and applicable legal requirements.

08:42 EDT IAA expands capacity in Iowa, Illinois - IAA announced the expansion of branches in Iowa and Illinois. Capacity has doubled at the IAA Des Moines branch and IAA St. Louis has increased capacity by approximately 30%. The expansions will help to meet increased demand in the growing Midwestern market.

08:41 EDT Sky Technologies names chair of architecural, real estate advisory board - SQL Technologies announced that Bernard Zyscovich will Chair Sky's newly formed Architectural and Real Estate Advisory Board. Bernard Zyscovich, Founder and CEO of Zyscovich Architects, is an internationally recognized design and thought leader in holistic master planning and Real Urbanism. Chaired by Mr. Zyscovich, Sky's Architectural and Real Estate Advisory Board is expected to drive the adoption of Sky's Plug Smart Platforms into multi-family residential buildings and communities.

08:39 EDT Dorman Products launches Shop Press hub - The company said, "Auto repair professionals and enthusiasts have a new destination for news, tips, stories and entertainment: Shop Press. Found at ShopPress.com, this new website is the news and idea hub for everything related to working on cars and trucks, focusing on repair, technology, and wrenching lifestyle. You'll find interesting stories from around the world, features on creative people and solutions, and all kinds of other original content that'll make you use your mind and your hands. Right now, you can read why every shop should have a welder, learn the easiest way to remove a cotter pin, hear the fascinating history of turbochargers, get an update on how Right to Repair legislation could affect service centers, meet the first technician to win a national auto repair competition, and listen to the definitive automotive music playlist. New articles and videos will be published weekly."

08:37 EDT PLBY Group appoints Hill to board of directors - PLBY (PLBY) announced the appointment of Juliana Hill to its Board of Directors, where she will serve as chair of the Audit Committee. Hill also serves on the Board of Directors and as Chair of the Audit Committee of National CineMedia (NCMI).

08:36 EDT ShockWave Medical announces Japanese regulatory approval of Coronary IVL - Shockwave Medical announced that the Shockwave C2 Coronary IVL Catheter received the regulatory approval in Japan. The approval of Shockwave C2 was supported by 30-day results from the Disrupt CAD IV study, a prospective, multicenter study to assess the safety and effectiveness of IVL in 64 Japanese patients that was published last year in Circulation Journal. The study met the primary safety endpoint and effectiveness endpoint with rates of 93.8 percent, which were consistent with results from the Disrupt CAD III study. "We are delighted to be partnering with the Japanese Association of Cardiovascular Intervention and Therapeutics to make this therapy available to the expert cardiologists in Japan," said Doug Godshall, Chief Executive Officer of Shockwave Medical. "With Japan's worldwide leadership in the adoption of intravascular imaging and systematic approach to optimizing lesion preparation, we are confident that CVIT will be the perfect partner to help ensure that coronary IVL will play a vital role in the future calcium treatment algorithms of Japanese physicians." With the Japan Pharmaceuticals and Medical Devices Agency classifying the Shockwave C2 Coronary IVL Catheter as a new medical device, Shockwave will now await reimbursement approval from the Japanese Ministry of Health, Labour and Welfare

08:35 EDT QuickLogic wins new $1.5M eFPGA contract - QuickLogic has won a new eFPGA contract. The contract is worth approximately $1.5M, bringing the aggregate value of eFPGA contracts in the last three quarters alone to more than $5M. A small amount of contract revenue was recorded in Q1 with the remainder to be recognized over the rest of FY22. There is no change to Q1 revenue guidance range and outlook for FY22 growth provided February 16.

08:34 EDT SciSparc appoints Avi Schroeder to Scientific Advisory Board - SciSparc announced the appointment of Professor Avi Schroeder as a member of the Company's Scientific Advisory Board. As a member of the SAB, Prof. Schroeder will support the development of the Company's top-tier, proprietary, investigational drug candidate SCI-160 program for the treatment of pain. Prof. Schroeder will advise the Company on the formulation development of SCI-160 to enhance the proprietary synthetic CB2 receptor agonist's biological effect and extend effect duration. Prof. Schroeder is the head of the Targeted Drug Delivery and Personalized Medicine Group, at the Technion, Israel Institute of Technology and has translational experience with the development of liposome-based clinical systems.

08:32 EDT CVS Health to settle all opioid claims against it by Florida for $484M - CVS Health announced that it has entered into an agreement with the State of Florida to resolve claims dating back more than a decade related to prescriptions for opioid medications that were filled at Florida CVS Pharmacy locations. Under the agreement the company will settle all opioid claims against it by Florida for $484M, to be paid over a period of 18 years. As a result, CVS Pharmacy will no longer be a defendant in Florida's opioid lawsuit that is scheduled for trial in April. The settlement amount is expected to be used by the State of Florida to support its efforts to combat opioid addiction and abuse. The settlement with the State of Florida includes no admission of wrongdoing. As a result of the unique facts and circumstances of the Florida claims, the settlement value should not be extrapolated to any other opioid-related litigation in which CVS Health is involved. CVS Health will continue to vigorously defend against other lawsuits relating to opioids.

08:26 EDT Avinger announces issuance of three new U.S. patents - Avinger announced the issuance of three new U.S. patents in March 2022 and provided an update on the expansion of its intellectual property portfolio. The following three new U.S. patents expanding intellectual property protection for Avinger's proprietary imaging platform and image-guided therapeutic devices were issued in March 2022: U.S. patent 11,284,839, Optical Coherence Tomography for Biological Imaging, broadens coverage for Avinger's proprietary OCT imaging platform. U.S. patent 11,284,916, Atherectomy Catheters and Occlusion Crossing Devices, expands coverage for Avinger's Pantheris OCT-guided family of atherectomy catheters. U.S. patent 11,278,248, OCT Imaging Catheter with Lag Correction, expands intellectual property protection related to Avinger's Tigereye image-guided CTO-crossing catheters. Avinger increased its patent portfolio significantly over the past year, with 12 new patents issued in the U.S. and 4 new patents issued in international markets. With the addition of these patents and new filings made during the year, Avinger's intellectual property portfolio now includes 187 patents and pending applications, including 49 issued and allowed patents in the U.S. and 77 issued and allowed patents outside the U.S. The portfolio has broad applicability in the areas of atherectomy, CTO-crossing and intravascular imaging for both peripheral and coronary applications.

08:22 EDT AGF Management raises quarterly dividend 11% to C$0.10 per share - AGF's Board of Directors has approved an 11% increase to the quarterly dividend for shareholders of record on April 8, 2022. On March 29, 2022, the Board of Directors of AGF Management Limited declared a dividend of $0.10 per share on both the Class B Non-Voting shares and the Class A Voting common shares of the company. This dividend will be payable on April 20, 2022 to shareholders of record on April 8, 2022.

08:18 EDT Collegium announces Master Settlement Agreement for opioid-related litigation - Collegium Pharmaceutical announced the execution of a Master Settlement Agreement resolving all 27 pending opioid-related lawsuits brought against the Company by cities, counties, and other subdivisions in the United States on March 18, 2022. The execution of this Master Settlement Agreement represents the implementation of a previously announced settlement framework with these parties in December 2021. As part of the Master Settlement Agreement, the Company paid $2.75M to the plaintiffs and the cases will be dismissed, with prejudice, in the coming weeks. The Company entered into the Master Settlement Agreement to efficiently resolve this litigation without an admission of liability or wrongdoing.

08:17 EDT Alignment Healthcare celebrates one year as public company - Alignment Healthcare marked one year of being publicly listed. "Over the past year, we've continued to set ourselves apart with our proven ability to improve care while lowering costs," said John Kao, founder and CEO, Alignment Healthcare. "We've grown into new markets and deliver products that are responsive and highly relevant to the changing needs of our seniors. We continued to invest in innovative platforms that scale our impact to our members while sustaining our strong business results." The one-year milestone builds upon a successful 2021, both financially and operationally, in the public markets. Compared to 2020, Alignment's full-year total revenue was $1.17 billion, a 21.7 percent jump year-over-year. This was led by its health plan premium revenue of $1.12 billion, an increase of 28.4 percent year-over-year. "Our business results reflect that we can do well by doing good, and we're committed to continuing our path of sustainable growth for the long term," Kao said.

08:15 EDT Prometheus initates third Phase 2 study of PRA023 for SSc-ILD - Prometheus Biosciences announced it has enrolled its first patient in the ATHENA-SSc-ILD trial, a placebo-controlled and statistically powered Phase 2 study of PRA023 in SSc-ILD. The Company announced in January 2021 that PRA023 received Fast Track Designation from the US Food and Drug Administration for the treatment of SSc-ILD. "PRA023, our anti-TL1A antibody, has shown the potential to be a differentiated, best-in-class precision therapy for multiple immune-mediated diseases and we now have three Phase 2 trials underway, demonstrating PRA023's pipeline-in-a-product opportunity," said Mark McKenna, Chairman and CEO of Prometheus. "Prometheus' initiation of ATHENA-SSc-ILD exemplifies our team's strong execution, marking the first indication of PRA023 outside of IBD."

08:15 EDT Missfresh reports Q4 sales for Fresh Joy label up 300% vs. Q1 - Missfresh saw fourth-quarter 2021 sales for its private label Fresh Joy product range grow 300%, as compared to the first quarter in the same year. This surge in sales is a result of Missfresh's continued investment in and improvements to the private label products' quality as well as increased customer trust and recognition of Missfresh's in-house brands.

08:13 EDT Resorts WorldBET, Genius Sports partner on new mobile sportsbook in New York - Genius Sports Limited has clinched a new partnership with Resorts WorldBET, the new mobile sports betting app for Resorts World New York, with brick-and-mortar casinos Resorts World Catskills RWC and Resorts World New York City RWNYC, to help power the digital sportsbook. Genius Sports will help Resorts WorldBET, which launched earlier this month in the Empire State, offer a market leading mobile sportsbook, providing its leading LiveData and LiveTrading solutions, powered by the highest quality official data. This new partnership will include Genius Sports' proprietary suite of NASCAR's official data-driven in-race betting markets in addition to exclusive NFL official sports data-powered products, including access to the league's real-time statistics, proprietary Next Gen Stats (NGS) and official sports betting data feed. In order to deliver a 24/7 offering to its customers, Resorts WorldBET will also receive real-time data feeds and in-point pricing for the English Premier League alongside dozens of FIBA basketball and FIVB volleyball leagues worldwide. As the fourth most populous state in the U.S., New York is widely projected to become one of the largest for online sports betting in 2022.

08:11 EDT INmune Bio CSO to co-host 'NK Cells in Solid Tumors' workshop - INmune Bio is pleased to announce the Company's Chief Scientific Officer Dr. Lowdell will be leading a workshop on the role of natural killer cells in the treatment of solid tumors. The presentation, titled, "Challenges of NK Immunotherapy of Solid Tumors: Potentiation of intra-tumoral NK Function," is part of the 7th Innate Killer Summit being held in San Diego from March 30 to April 1. Prof. Lowdell has identified several of the problems to be discussed, and addressed: What is the best way to deliver a cancer killing NK cell? The different strategies to deliver NK cell therapies include a complex mix of genetic engineering, cytokine use, ex-vivo processing and manufacturing. Complexity is a barrier to use. How do we improve the delivery of effective NK cell therapy to patients? Persistence of NK cell killing is important for success - Short survival of NK therapeutics hampers efficacy. Are there ways to improve therapeutic persistence of tumor killing NK cells? Why is the therapeutic response to NK therapies suboptimal in solid tumors? The hostile biology of the tumor micro-environment in solid tumors affects the activity of NK cells in many ways. Identifying and overcoming barriers to NK function in the TME will improve the chance of success. Logistics and delivery: NK cell therapies must balance therapeutic value with practicality and access. The manufacture, storage, and delivery of NK cell therapeutics can be complex. Strategies to simplify these steps will speed adoption of these therapies by the medical community. Mark Lowdell will further discuss INKmune Patient Case Studies: Since the last Innate Killer Summit, INmune has treated three patients with INKmune and will share these results with the NK community at the conference. The first MDS patient, a 74-year-old man, remains stable 9 months after therapy. Updated results at the lowest dose cohort of INKmune treatment at day 119 show: NO side effects - NO evidence of alloresponse to INKmune; Evidence of disease control and maintenance of MRD after 3 doses; Improved BM function - No G-CSF / Platelet independent; Improved ECOG score from 2 to 0; Production of tumor killing memory like NK cells; Persistence of activated NK cells in blood to Day 119 at least; A 21-year-old female with relapsed AML and mixed chimerism after stem cell transplant reestablished 100% donor chimerism after INKmune therapy. She remains under close observation as an out-patient more than 6 months after INKmune therapy. The third patient, a young man with AML who failed two transplants remains desperately ill.

08:08 EDT Brunswick: Mercury Marine captures share at Palm Beach International Boat Show - Mercury Marine continues to expand its presence and grow market share at key saltwater boat shows. During the Palm Beach International Boat Show this past weekend, Mercury captured close to 60% share of total outboard engines at the show and almost 70% share of all outboard engines over 200hp on the water. This marks the largest share of outboard engines for Mercury at a Florida show and continues its share gains during key Florida boat shows including Miami and Ft. Lauderdale.

08:07 EDT Avinger issued three new U.S. patents in March - Avinger announced the issuance of three new U.S. patents in March and provided an update on the expansion of its intellectual property portfolio. The following three new U.S. patents expanding intellectual property protection for Avinger's proprietary imaging platform and image-guided therapeutic devices were issued in March 2022: U.S. patent 11,284,839, Optical Coherence Tomography for Biological Imaging, broadens coverage for Avinger's proprietary OCT imaging platform. U.S. patent 11,284,916, Atherectomy Catheters and Occlusion Crossing Devices, expands coverage for Avinger's Pantheris OCT-guided family of atherectomy catheters. U.S. patent 11,278,248, OCT Imaging Catheter with Lag Correction, expands intellectual property protection related to Avinger's Tigereye image-guided CTO-crossing catheters. Avinger increased its patent portfolio significantly over the past year, with 12 new patents issued in the U.S. and four new patents issued in international markets. With the addition of these patents and new filings made during the year, Avinger's intellectual property portfolio now includes 187 patents and pending applications, including 49 issued and allowed patents in the U.S. and 77 issued and allowed patents outside the U.S. The portfolio has broad applicability in the areas of atherectomy, CTO-crossing and intravascular imaging for both peripheral and coronary applications.

08:06 EDT Vivid Seats strengthens partnership with Capital One - Vivid Seats (SEAT) announced it has strengthened its partnership with Capital One Financial Corporation (COF), with the launch of Capital One Entertainment, a new ticketing platform for Capital One rewards cardholders that will allow them to redeem their rewards for tickets to more than 500,000 events. Built and powered by Vivid Seats, this digital-first booking experience enables Capital One cardholders to browse and purchase or redeem rewards for tickets to more than 500,000 events using rewards, a card, or a combination of both. "We are proud to deepen our partnership with Capital One and create this new experience for Capital One customers," said Geoff Lester, Chief Commercial Officer at Vivid Seats. "We look forward to providing them with seamless access to unforgettable experiences by leveraging our marketplace inventory, technology, fulfillment, and customer service capabilities, in a way only Vivid Seats can."

08:04 EDT Compass Therapeutics announces presentation on CTX-8371 at 2022 AACR meeting - Compass Therapeutics announced that it will present preclinical data on CTX-8371, a next generation bispecific checkpoint inhibitor that simultaneously targets PD-1 and PD-L1 at the upcoming American Association for Cancer Research, AACR, Annual Meeting, which is being held April 8-13, 2022, at the Ernest N. Morial Convention Center in New Orleans, Louisiana. Presentation Title: "Dose Range Finding Study in Non-human Primates Confirms the Unique Mechanism of Action of CTX-8371, a Novel Bispecific Antibody Blocking PD-1 and PD-L1."

08:04 EDT IBM partners with Discover to enhance digital transformation of systems - IBM Consulting (IBM) is working with Discover Financial Services (DFS) to help the leading digital bank and payments company enhance its digital transformation of applications and existing systems to a hybrid cloud architecture using Red Hat OpenShift. Discover plans to migrate and modernize its current systems and applications to an open and flexible hybrid cloud architecture. Red Hat OpenShift will help Discover leverage key capabilities such as security, automation and multicloud service integration to reduce operational costs, deliver better outcomes across business processes, enable faster application deployments, and bring agility with enhanced security and resilience. IBM Consulting also will collaborate with Discover's teams to utilize IBM Garage and agile techniques to modernize existing applications and co-create new solutions to help Discover derive greater business and technical benefits. Discover will use Red Hat Ansible Automation Platform for hybrid cloud automation and Red Hat Advanced Cluster Management for Kubernetes to achieve end-to-end management visibility and control of its cluster and application lifecycle across its hybrid cloud architecture.

08:03 EDT AC Immune KOL webinar on first clinical proof of concept for ACI-12589 - AC Immune hosted key opinion leader, KOL, Dr. Oskar Hansson for a webinar focused on a-synuclein as a diagnostic and therapeutic target in neurodegenerative diseases. AC Immune and Dr Hansson reported at the recent AD/PD conference, data showing that AC Immune's wholly owned a-syn PET tracer ACI-12589 was the first-ever radiotracer to distinguish multiple system atrophy, MSA, from other a-synucleinopathies, i.e. Parkinson's disease and Lewy body dementia, and healthy volunteers. Prof. Andrea Pfeifer, Ph.D., CEO of AC Immune SA, commented: "Together with our collaborators and leveraging our Morphomer discovery technology, AC Immune scientists continue to drive unparalleled research in neurodegenerative disease. This first clinical proof of concept for ACI-12589 in MSA opens new avenues in translational medicine including a regulatory pathway to discuss biomarker-based development for NeuroOrphan indications. The very first PET images of a-syn in living human brains represent a fundamental advance for the whole neurodegenerative research community. Differentiating MSA from other a-synucleinopathies using this radiotracer will enable more efficient trials, thanks to more accurate patient selection and improved measurements of the impact of targeted therapies. We believe this will accelerate the development of therapeutics for MSA, PD and DLB and contribute to realizing the promise of precision medicine for neurodegenerative diseases. Importantly, an effective tracer will potentially enable the diagnosis and selection of patients with early-stage disease, thereby improving the chances of successfully developing vaccines to reduce or prevent disease progression." During the Webinar, Dr. Hansson provided key points on ACI-12589 data from the first clinical proof-of concept study: ACI-12589 shows a rapid brain uptake and fast signal equilibrium; Standardized Uptake Value Ratio can be used with occipital or cerebellar grey reference region; Strong binding in expected regions in MSA and complete separation of MSA from other a-synucleinopathies and controls;ACI-12589 is a promising PET tracer supporting a diagnosis of MSA and a-synuclein drug target engagement.

08:02 EDT ATIF Holdings wins new advisory services contract for $1.3M in China - ATIF Holdings has been retained by a technology innovation company based in Hangzhou, China, for consulting and IPO Advisory services. The total contract value is $1.27M of which ATIF has received the first installment payment in the amount of $381K. The client provides design, development, construction, and operation services in connection with urban smart parking, parking lot renovation, and Internet of Things products. The client plans to become a public company via an initial public offering or reverse takeover by the end of 2022.

07:48 EDT Skeena Resources files early warning report in respect of QuestEx acquisition - Skeena Resources Limited (SKE) reports that, on March 29, 2022, it entered into an arrangement agreement with QuestEx Gold & Copper whereby Skeena agreed to acquire, subject to the terms and conditions thereof, ownership and control of all of the issued and outstanding Common Shares of QuestEx not owned by Skeena from the shareholders of QuestEx pursuant to an arrangement undertaken in accordance with the provisions of the Business Corporations Act. Except with respect to the consideration payable to Newmont Corporation (NEM) which will be satisfied pursuant to the issuance of a promissory note, in consideration for the acquisition of each Common Share not held by Skeena, Skeena will pay $0.65 in cash and issue 0.0367 Skeena common shares. Based on the 5 day volume-weighted average price of the Skeena common shares on the TSX for the 5 day period ending March 29, 2022, the Consideration payable for each Common Share not owned by Skeena is approximately $1.20. In respect of the Consideration payable and issuable to Newmont Corporation, Skeena will issue to Newmont a promissory note representing its entitlement to the Consideration instead of issuing Skeena common shares and paying cash to Newmont on the closing of the Arrangement. Assuming no Common Shares are issued prior to the closing of the Arrangement, and taking into account the promissory note issuable to Newmont, Skeena will pay $18,474,588.60 and issue 1,043,103 Skeena shares on the closing of the Arrangement, less any fractional shares rounded down pursuant to the provisions of the Arrangement Agreement. On the date hereof, Skeena owns 5,668,642 Common Shares, representing 14.0% of the issued and outstanding Common Shares of QuestEx. Upon completion of the Arrangement, Skeena will own all of the issued and outstanding Common Shares of QuestEx. Assuming no Common Shares are issued prior to the closing of the Arrangement, Skeena will acquire 34,807,205 Common Shares on the closing of the Arrangement. Skeena is acquiring QuestEx in order to increase its land package in British Columbia's "Golden Triangle" region and to unlock potential synergies and opportunities presented by QuestEx's property portfolio. If the Arrangement is completed, QuestEx will become a wholly-owned subsidiary of Skeena, under the control of Skeena, and Skeena will apply for QuestEx to cease being a reporting issuer in Canada and for the Common Shares to cease trading on the TSX Venture Exchange. Concurrently with the execution of the Arrangement Agreement, Skeena entered into an asset purchase agreement with an affiliate of Newmont, pursuant to which, conditional on the Arrangement becoming effective, the Purchaser will acquire, indirectly from Skeena, all beneficial and legal right, title and interest to the Castle, North ROK, Heart Peaks, Moat and Coyote properties in northwestern British Columbia and certain related assets, which are assets that are currently owned by QuestEx. If the Arrangement is not completed, Skeena will continue to hold its Common Shares for investment purposes.

07:46 EDT Skeena Resources to acquire QuestEx for C$48.6M in cash, shares - Skeena Resources (SKE) is pleased to announce that it has signed a binding agreement with QuestEx Gold & Copper whereby Skeena will acquire all of the issued and outstanding shares of QuestEx, pursuant to a plan of arrangement for share and cash consideration. The consideration will consist of C$0.65 cash and 0.0367 of a common share in the capital of Skeena for each one QuestEx common share, representing total consideration of approximately C$48.6 million, or approximately C$1.20 per QuestEx share based on Skeena's 5-day VWAP ending March 29, 2022, on the TSX. Skeena has signed a concurrent binding agreement with Newmont Corporation (NEM) to vend certain QuestEx properties to Newmont via an asset purchase agreement on completion of the QuestEx Transaction for approximately C$27 million. The cash proceeds from the Newmont Transaction are expected to be sufficient to cover the cash portion of the aggregate Arrangement Consideration payable by Skeena. The net Arrangement Consideration will be payable through the issuance of approximately C$15 million in Skeena Shares. Skeena will also assume QuestEx's outstanding options and warrants. Under the terms of the binding agreement dated March 29, 2022, between Skeena and QuestEx, each of QuestEx's issued and outstanding common shares will be exchanged for C$0.65 cash and 0.0367 of a Skeena Share, representing total consideration of approximately C$1.20 per QuestEx share based on Skeena's 5-day VWAP ending March 29, 2022, on the TSX. Pursuant to the Arrangement Agreement, the QuestEx Acquisition will be carried out by way of a court approved plan of arrangement and will require the approval of at least 66 2/3% of the votes cast by shareholders of QuestEx, voting as a single class and shareholders, option holders and certain warrant holders of QuestEx, voting as a single class, in each case that are present in person or by proxy at a special meeting expected to be held in May of 2022 and, pursuant to Multilateral Instrument 61-101 - Protection of Minority Securityholders in Special Transactions, a simple majority of the votes cast by shareholders of QuestEx present in person or by proxy after excluding any votes of "related parties" and "interested parties' and other persons required to be excluded under 61-101, all at a special meeting to consider the Transaction. The Arrangement Agreement includes customary deal-protection provisions, including non-solicitation provisions, a right to match in the event of a superior proposal and a termination fee or expense reimbursement payable under certain circumstances. Full details of the QuestEx Acquisition will be included in the management information circular of QuestEx to be mailed in respect of the QuestEx Meeting. Completion of the QuestEx Transaction is subject to the fulfillment of each of the conditions precedent to the Newmont Transaction that are capable of being fulfilled prior to the closing of the QuestEx Transaction. The Board of Directors of each of Skeena and QuestEx have unanimously approved the Arrangement Agreement. Certain significant shareholders of QuestEx and the directors and senior officers of QuestEx have entered into voting support agreements pursuant to which each has agreed to vote all of their QuestEx securities in favour of the QuestEx Acquisition. Collectively, the Supporting Shareholders own approximately 27% of the outstanding common shares of QuestEx. Skeena and Newmont have entered into a binding asset purchase agreement dated March 29, 2022, pursuant to which Newmont will purchase 100% of Skeena's rights, titles, and interests, on completion of the QuestEx Transaction, in and to the Heart Peaks, Castle, Moat, Coyote, and North ROK properties, currently owned by QuestEx, in exchange for cash consideration of approximately C$27 million. The consideration payable to Skeena pursuant to the Newmont Transaction will be set off against the Arrangement Consideration payable and issuable to Newmont pursuant to the QuestEx Transaction, with the remaining amount payable by Newmont under the Newmont Transaction being sufficient to cover the cash portion of the aggregate Arrangement Consideration payable pursuant to the QuestEx Transaction. Completion of the Newmont Transaction is subject to completion of the QuestEx Transaction. Subject to QuestEx shareholder approval, regulatory approval (including TSXV and TSX) and the fulfillment of other customary closing conditions, the Company expects to close the QuestEx Transaction and Newmont Transaction on or about June 2, 2022.

07:41 EDT Churchill Downs announces proposed offering of $900M of senior notes - Churchill Downs announced that CDI Escrow Issuer, a wholly owned subsidiary of CDI, intends to offer, subject to market and customary conditions, $900M in aggregate principal amount of senior notes due 2030 in a private offering. The offering of the Notes is part of the financing for the proposed acquisition by CDI of substantially all of the assets of Peninsula Pacific Entertainment, a Delaware limited liability company. The proceeds of the proposed offering will be placed in escrow pending satisfaction of certain conditions, including, without limitation, the consummation of the Acquisition. Upon satisfaction of such escrow conditions, CDI will assume the Escrow Issuer's obligations under the Notes and the indenture that will govern the Notes, and certain of CDI's subsidiaries, after giving effect to the Acquisition, will guarantee CDI's obligations under the Notes. Upon satisfaction of the escrow conditions, CDI intends to use the net proceeds from the offering, together with borrowings under the senior secured credit facilities, to finance the consummation of the Acquisition and pay related transaction fees and expenses.

07:38 EDT Skeena Resources to acquire QuestEx - Skeena Resources (SKE) announced that it has signed a binding agreement with QuestEx Gold & Copper whereby Skeena will acquire all of the issued and outstanding shares of QuestEx, pursuant to a plan of arrangement for share and cash consideration. The consideration will consist of C$0.65 cash and 0.0367 of a common share in the capital of Skeena for each one QuestEx common share, representing total consideration of approximately C$48.6M, or approximately C$1.20 per QuestEx share based on Skeena's five-day VWAP ending March 29, on the TSX. Skeena has signed a concurrent binding agreement with Newmont (NEM) to vend certain QuestEx properties to Newmont via an asset purchase agreement on completion of the QuestEx Transaction for approximately C$27M. The cash proceeds from the Newmont Transaction are expected to be sufficient to cover the cash portion of the aggregate arrangement consideration payable by Skeena. The net arrangement consideration will be payable through the issuance of approximately C$15M in Skeena Shares. Skeena will also assume QuestEx's outstanding options and warrants.

07:35 EDT Biogen submits final protocol for ADUHELM Phase 4 ENVISION trial to FDA - Biogen has submitted the final study protocol for the confirmatory Phase 4 ENVISION trial to the U.S. Food and Drug Administration, FDA, for review and approval. This is in line with the company's commitment to accelerate the timelines for the trial, including submitting the final study protocol to the FDA in March 2022, as previously announced. Biogen expects the first patient to enter screening in May 2022 and the trial's primary completion approximately four years after the study begins. The confirmatory ENVISION trial is a requirement based on FDA's accelerated approval of ADUHELM 100 mg/mL injection for intravenous use in early Alzheimer's disease. The study, as previously announced, will be a global, placebo-controlled trial, aiming to enroll around 1,500 patients with early Alzheimer's disease and confirmation of amyloid beta pathology. The company has also reaffirmed the trial's goal of recruiting at least 18 percent of patients in the U.S. from Black/African American and Latino communities. The primary endpoint for the trial will be measured by the Clinical Dementia Rating-Sum of Boxes at 18 months, as announced in January 2022. The trial will also include a planned long-term extension to collect treatment data for up to 48 months. Secondary endpoints include changes in Amyloid Positron Emission Tomography and Tau PET, as well as the Alzheimer's Disease Assessment Scale-Cognitive Subscale, Alzheimer's Disease Cooperative Study - Activities of Daily Living Inventory - Mild Cognitive Impairment Version, Integrated Alzheimer's Disease Rating Scale, Mini-Mental State Examination and Neuropsychiatric Inventory.

07:35 EDT Alaunos Therapeutics expects cash to fund operations into 2Q23 - As of December 31, 2021, Alaunos had approximately $76.1 million in cash and cash equivalents. The Company anticipates its cash runway will be sufficient to fund operations into the second quarter of 2023.

07:31 EDT Replimune Group provides data on its PP2/3 development strategy - Replimune announced updated data from completed cohorts of the Phase 2 part of the IGNYTE clinical trial in non-melanoma skin cancer, NMSC, and melanoma. Additionally, the Company announced new data from the ongoing clinical trial in anti-PD1 failed NMSC and from the ARTACUS clinical trial, a Phase 1b/2 trial of RP1 as monotherapy in solid organ transplant recipients with skin cancer. RP2/3 Development Strategy: RP2 leverages the Company's platform to express an anti-CTLA-4 antibody, in addition to the GALV-GP R- and GM-CSF expressed by RP1. The Company will review data from the Phase 1 clinical trial of RP2 alone and in combination with Opdivo and announce its development strategy for the Phase 2 clinical development of RP2/3. After fully enrolling patients in the RP2 monotherapy and combination with Opdivo cohorts in the Phase 1 clinical trial with RP2, a further cohort of Phase 1 patients with tumor types of particular interest was recently opened. RP3 further expresses CD40L and 4-1BBL in addition to anti-CTLA-4 and GALV-GP R-, is intended to induce a broad and potent anti-tumor immune response, and for which a Phase 1 clinical trial is also underway. The higher dose level has been confirmed as the recommended Phase 2 dose. The first six patients enrolled in this Phase 1 clinical trial had heavily pre-treated advanced sarcoma, esophageal cancer, colorectal cancer, head and neck cancer and melanoma. Three of the six patients died due to disease progression approximately two to four months from initiating the study, indicating the advanced nature of disease of the patients enrolled. Two other patients also had rapid progressive disease, and one patient with esophageal cancer had stable disease out to one year. Enrollment into the cohort of patients dosed with RP3 combined with Opdivo has also recently commenced. This cohort will focus on enrolling patients with GI cancers, breast cancer, lung cancer and head and neck cancer.

07:28 EDT CureVac, GSK start clinical development of CV2CoV COVID-19 vaccine candidate - CureVac N.V. (CVAC) announced that the first participant was dosed in a Phase 1 study of COVID-19 second-generation mRNA vaccine candidate, CV2CoV, developed in collaboration with GSK (GSK). The clinical trial is expected to provide valuable data to further evaluate the performance of CureVac's second-generation mRNA backbone, which has the potential to be applied broadly in future vaccines against COVID-19 variants and other pathogens. A preclinical study of CV2CoV in cynomolgus macaques, published in Nature in November 2021, demonstrated rapid induction of higher antibody titers, better induction of immune memory and stronger protective efficacy of CV2CoV compared to CureVac's first-generation vaccine candidate, CVnCoV. The same study demonstrated comparable neutralizing antibody titers in animals fully vaccinated with either 12microgram of CV2CoV or a 30microgram standard dose of a licensed mRNA COVID-19 vaccine. The Phase 1 dose-escalation study is being conducted at clinical sites in the U.S. and is expected to enroll up to 210 healthy adults to evaluate the safety, reactogenicity and immunogenicity of CV2CoV in the dose range of 2 to 20microgram. Data results from the Phase 1 study are expected in the second half of 2022. The program follows the recent start of the Phase 1 clinical study for the jointly developed seasonal influenza vaccine candidate, CVSQIV, also applying the optimized second-generation mRNA backbone. The CureVac-GSK infectious disease collaboration was first announced in July 2020 and focuses on the development of new products based on CureVac's mRNA technology for different targets in the field of infectious diseases. In 2022, both companies have broadened their development strategy to test chemically modified mRNA technologies in addition to unmodified mRNA. Clinical programs with chemically modified mRNA for COVID-19 and influenza are expected to start later this year.

07:23 EDT Graybug Vision expects cash to deliver three clinical readouts in 2023 - "We are very excited to move GB-102 into a Phase 2 clinical trial in wet AMD in the fourth quarter of 2022, while expanding our pipeline to address additional vision-threatening retinal and corneal diseases with high unmet patient needs. We plan to use our current cash to advance GB-102, GB-401 and GB-501 to clinical readouts in 2023," said Fred Guerard, PharmD, CEO of Graybug.

07:23 EDT Graybug Vision announces update on pipeline programs - Graybug Vision announced a strategic update on its pipeline programs GB-102 in wet age-related macular degeneration, GB-401 in primary open-angle glaucoma, as well as its newly acquired assets in corneal disease, inherited retinal diseases, and geographic atrophy. GB-102 for wet AMD: Graybug plans to proceed with a Phase 2 clinical trial of an optimized formulation of GB-102 in wet AMD patients following successful demonstration of improved performance in an extensive battery of novel in vitro stress tests. This decision, supported by a significantly more favorable competitive landscape following recent readouts of other long-acting vascular endothelial growth factor inhibitors, is anticipated to result in a six-month data readout available in the third quarter of 2023. GB-401 for POAG: In glaucoma, poor patient compliance with eye drops frequently results in suboptimal control of intraocular pressure, and degeneration of the optic nerve, leading to irreversible vision loss. GB-401 is a potentially first-in-class implant formulation containing a novel prodrug of timolol injected intravitreally with a proprietary applicator, targeting twice-yearly treatment. Initiation of a Phase 1 trial with GB-401 is planned for the first quarter of 2023, with safety and efficacy data expected to be available in the second quarter of 2023. GB-501 for MPS1 Corneal Clouding: Graybug recently acquired RainBIO, a start-up company based in North Carolina, that developed a first-in-class gene therapy for mucopolysaccharidosis type 1 (MPS1), an inherited lysosomal storage disorder with very high prevalence of corneal clouding despite existing systemic therapies. GB-501 received Orphan Drug Designation from the FDA and is eligible for a Priority Review Voucher upon approval. Preclinical studies in a dog model of MPS1 demonstrated complete and sustained clearing of the cornea in all dogs, regardless of disease severity, in less than a month following a single intrastromal injection. Two-year animal data support the potential for GB-501 to cure corneal clouding and restore vision in MPS1 patients. All patients required for the Phase 1/2a trial have been identified, IND submission is expected in the second quarter of 2023, and the data readout is expected in the fourth quarter of 2023. GB-601 for Inherited Retinal Diseases: Inherited retinal disorders such as retinitis pigmentosa, Leber's congenital amaurosis, and Stargardt's disease are the consequence of over 280 genetic mutations. To date, only one drug has been approved to address a single mutation, which accounts for a very small fraction of IRDs, leaving the vast majority of patients without therapeutic options. Graybug recently acquired a portfolio of novel cGMP analogs, supported by a well-characterized mode of action and preclinical data in established RP disease models, from Mireca Medicines GmbH, a German preclinical start-up company. Graybug is developing these cGMP analogs as first-in-class, mutation-agnostic long-acting therapeutics to treat a majority of patients with these diseases. GB-701 for Geographic Atrophy: Geographic atrophy represents a significant unmet medical need with over five million patients worldwide suffering from this late-stage, age-related macular degeneration for which there is currently no FDA approved treatment. Recent clinical trials have indicated that targeting the complement pathway is suitable for slowing disease progression, but these investigational therapies require up to 12 injections per year. Graybug and Insilico Medicine, a clinical-stage, end-to-end artificial intelligence-drug discovery company, recently formed a strategic partnership to leverage Insilico's AI-driven small molecule discovery platform with Graybug's unique ocular drug delivery technologies enabling Graybug to develop a sustained-release, locally administered ocular formulation of a potent factor B inhibitor as a potential treatment for this vision-threatening disease.

07:20 EDT Gritstone announces inducement grants under Nasdaq lsiting rule - Gritstone bio announced that the company's Board of Directors has granted five employees nonqualified stock options to purchase an aggregate of 14,800 shares of its common stock with an exercise price of $4.90, which is equal to the closing price of Gritstone's common stock on March 17, 2022, the grant date of the awards. These stock grants are part of an inducement material to each of the new employees becoming an employee of Gritstone, in accordance with Nasdaq Listing Rule 5635(c)(4). The stock options will vest over a four-year period, with 25% of the options vesting on the first anniversary of the employees' date of hire, and 1/48th of the options vesting monthly thereafter, subject to the employees' continued employment with Gritstone on such vesting dates. The options are subject to the terms and conditions of Gritstone's 2021 Employment Inducement Incentive Award Plan and the stock option agreement covering the grant.

07:16 EDT Orchard Therapeutics announces expected milestones - o advance its portfolio of gene therapies for neurometabolic disorders and investigate future applications for the HSC approach, Orchard has provided an updated list of expected milestones: Libmeldy launch: Reach a reimbursement agreement with one additional country in the first half of 2022, followed by additional agreements as negotiations are completed. OTL-200 for MLD: Conduct a pre-Biologics License Application meeting with U.S. Food and Drug Administration for OTL-200 in the second half of 2022 in advance of a BLA submission timeline of late 2022 to early 2023. OTL-203 for MPS-IH: Obtain the necessary Investigational New Drug application clearance in mid-2022 to enable the initiation of the OTL-203 registrational study in MPS-IH by year end 2022. OTL-201 for MPS-IIIA: Report clinical data, including early clinical outcomes of cognitive function, from the OTL-201 proof-of-concept trial by year end 2022. Research programs: Report preclinical POC data for the OTL-104 program in NOD2 Crohn's disease by year end 2022 and file an IND in 2024. Continue to advance the OTL-105 program in HAE, OTL-204 program for GRN-FTD and work in HSC-generated antigen-specific Tregs.

07:15 EDT Orchard Therapeutics sees cash runway into 2024

07:14 EDT Orchard Therapeutics reports Q4 EPS (29c), consensus (28c) - Reports Q4 revenue $483,000, consensus $300,000. "In light of our experiences and knowledge gained in this current and rapidly evolving market environment for gene therapy, our plan is to concentrate resources on programs that have the potential to make a remarkable difference to patients while also providing sustainable value to the business to enable the achievement our long-term vision," said Bobby Gaspar, M.D., Ph.D., chief executive officer. "As launch momentum for Libmeldy continues to build in Europe and we prepare for a regulatory filing in the U.S., a focused strategy that utilizes a common infrastructure for future neurometabolic disease launches is critical to our success as a commercial gene therapy company."

07:11 EDT Orchard to seek strategic alternatives for primary immunodeficiency programs - To support the company's refined strategic focus and provide runway extension into 2024, Orchard intends to discontinue its investment in and seek alternatives for its programs in rare primary immune deficiencies. These include OTL-103 for the treatment of Wiskott-Aldrich syndrome, OTL-102 for X-linked chronic granulomatous disease and Strimvelis, a gammaretroviral vector-based gene therapy approved in Europe for adenosine deaminase severe combined immunodeficiency. Regarding the regulatory status of the OTL-103 program in the U.S., Orchard recently received written feedback from the FDA. The company believes the path to a potential BLA filing may require additional time and further investment. CEO Bobby Gaspar continued, "We recognize the significant need that persists for many patients suffering from these rare diseases of the immune system, and we sympathize with the individuals, families and healthcare providers affected by these announcements, as well as our clinical partners and colleagues who worked so hard to advance these programs. These therapies have shown the potential for significant benefit for many patients treated in the clinical studies and we will continue to look for alternative ways to advance them, which could include commercial partnerships." As a result of these updates, the company has proposed to reduce its current workforce by approximately 30%, which will result in a restructuring charge in 2022. Collectively, the actions announced today are expected to extend the company's existing cash runway into 2024.

07:10 EDT Orchard Therapeutics intends to focus on HSC gene therapy platform - Orchard Therapeutics announced its intention to focus its hematopoietic stem cell gene therapy platform exclusively on severe neurometabolic diseases and early research programs while also reporting its financial results for the quarter and year ended December 31, 2021. These actions are intended to extend the company's cash runway into 2024 and focus operations on the highest value programs in its portfolio. Moving forward, Orchard will continue its investment in Libmeldy / OTL-200 for metachromatic leukodystrophy to help sustain recent commercial momentum in Europe, as well as to support regulatory and future commercial activities for a potential U.S. approval and launch. The company also will continue to advance clinical development of OTL-203 for mucopolysaccharidosis type I Hurler's syndrome and OTL-201 for mucopolysaccharidosis type IIIA. The focus on these neurometabolic programs is expected to allow Orchard to leverage the clinical validation of HSC gene therapy demonstrated with Libmeldy and capture significant commercial synergies, especially given the immense unmet needs in these diseases. Promising early-stage research programs that apply the HSC gene therapy approach in NOD2 Crohn's disease, hereditary angioedema and progranulin mutated frontotemporal dementia also will remain an important part of the portfolio going forward given their promise in larger indications and as a possible source of future partnerships.

07:07 EDT Five Below expects to triple store count to 3,500+ by end of 2030 - As part of today's Investor Day 2022, the Company is sharing its "Triple-Double" growth vision and long-term targets. Embedded in this vision are the following expectations: Triple store count to 3,500+ by the end of fiscal 2030; Achieve the following by the end of fiscal 2025: Double sales; More than double EPS; Grow operating margin to approximately 14%; Open approximately 1,000 stores: 375-400 new stores over the next two fiscal years; 550-600 new stores over fiscal years 2024 and 2025.

07:06 EDT Sol-Gel Technologies sees cash, cash equivalents funding operations through 2023 - As of December 31, 2021, Sol-Gel had $41.5M in cash, cash equivalents and deposits, and $1.7M in marketable securities for a total balance of $43.2M. As a result of our agreements with Galderma regarding EPSOLAY and TWYNEO and the agreement with Padagis, the Company expects that its cash resources will enable funding of operational and capital expenditure requirements through the end of 2023, assuming the timely approval of EPSOLAY. As of March 28, 2022, Sol-Gel had $31.6M in cash, cash equivalents and deposits, and $6.2M in marketable securities, for a total balance of $37.8M.

07:04 EDT Wallbox announces partnership with CES - Wallbox announced a partnership with City Electric Supply, or CES. Under this partnership, the family-owned electrical wholesale distributor has officially started to sell the 48 Amp version of Wallbox's smart home EV charger, Pulsar Plus, along with its Smart Power Meters and Pedestals online and in over 535 stores nationwide.

07:03 EDT AerCap sees impairment on assets in Russia as early as Q1 - The company stated, "In response to the Russian invasion of Ukraine on February 24, 2022, the United States, the European Union, the United Kingdom and other countries have imposed broad, far-reaching sanctions against Russia, certain Russian persons and certain activities involving Russia or Russian persons. These sanctions include prohibitions regarding the supply of aircraft and aircraft components to Russian persons or for use in Russia, subject to certain wind-down periods. AerCap intends to fully comply with all applicable sanctions and we have terminated the leasing of all our aircraft and engines with Russian airlines. As of December 31, 2021, approximately 5% of AerCap's fleet by net book value was on lease to Russian airlines. We continue to make efforts to repossess additional aircraft and engines from our former Russian airline customers, but it is unclear if we will be able to do so, or what the condition of these assets will be at the time of repossession. We expect to recognize an impairment on our assets in Russia that have not been returned to us as early as the first quarter of 2022, although we have not determined the amount of any impairment."

06:51 EDT Macy's appoints Marie Chandoha, Jill Granoff to Board of Directors - Macy's (M) announced the appointment of Marie Chandoha, former president and CEO of Charles Schwab (SCHW) Investment Management, and Jill Granoff, managing partner of Eurazeo and CEO of Eurazeo's Brands division, to its board of directors, effective April 1.

06:36 EDT Adagio Therapeutics reports Q4 EPS (77c), consensus ($1.03) - Cash, cash equivalents and marketable securities were $591.4M as of December 31, 2021. Expects its existing cash, cash equivalents and marketable securities will enable the company to fund its operating expenses and capital expenditure requirements into the second half of 2024. "COVID-19 continues to pose significant challenges globally as waning immunity combined with the emergence of resistant variants has led to ongoing waves of disease. We believe that a suite of options - spanning prophylaxis and treatment - is needed to effectively address this virus as it continues to evolve, and these data give us confidence in the potential role adintrevimab can play in physicians' arsenals," said interim CEO and COO David Hering. "Based on the data from both EVADE and STAMP, including the impacts observed in preliminary analyses from participants enrolled after the emergence of the Omicron variant, our team is initiating discussions with the FDA and preparing an EUA submission for adintrevimab. With more than one million doses of adintrevimab secured for 2022 and a solid financial position expected to take us into the second half of 2024, we are optimistic about the road ahead and the impact adintrevimab could have for the many people around the globe, particularly those at high risk with co-morbidities, who continue to need options."

06:33 EDT Adagio Therapeutics' ADG20 meets primary Phase 2/3 endpoints in COVID-19 - Adagio Therapeutics reported that the primary endpoints were met with statistical significance for all three indications in the company's ongoing global Phase 2/3 clinical trials evaluating its investigational drug adintrevimab - ADG20 - as a pre-and-post-exposure prophylaxis (EVADE) and treatment (STAMP) for COVID-19. EVADE and STAMP were primarily conducted during a time when pre-Omicron SARS-CoV-2 variants were dominant. Following the emergence of the Omicron variant, in a pre-specified exploratory analysis in a subset of the pre-exposure cohort, a clinically meaningful reduction in cases of symptomatic COVID-19 was observed with adintrevimab compared to placebo. Across both trials, a single intramuscular (IM) administration of adintrevimab at the 300mg dose had a similar safety profile to that of placebo. Based on these data, Adagio plans to engage with the FDA and to submit an Emergency Use Authorization application in 2Q22 for adintrevimab for both the prevention and treatment of COVID-19. In addition, Adagio provided an update on its ongoing Phase 1 study evaluating adintrevimab at higher doses and on research activities related to adintrevimab re-engineering and the identification of new antibodies to potentially address COVID-19 and other viruses. Risk of symptomatic COVID-19 was reduced by 71% compared to placebo in pre-exposure prophylaxis and 75% compared to placebo in post-exposure prophylaxis. Risk of hospitalization or death in participants with mild to moderate COVID-19 was reduced by 66% compared to placebo in the primary efficacy analysis population and by 77% compared to placebo in participants who received treatment within three days of symptom onset.

06:21 EDT Greenbrier elects CEO Lorie Tekorius to board - Greenbrier announced that president and CEO, Lorie Tekorius, has been elected to its board of directors. Following her promotion to CEO on March 1, the election of Tekorius increases Greenbrier's board from 10 to 11 members. She is expected to be nominated for a three-year term to the board for election at Greenbrier's annual meeting of shareholders in January 2023.

06:17 EDT BioNTech expects to propose special cash dividend of EUR 2.00 per share - Pending approval at the Annual General Meeting.

06:13 EDT Sonoma Pharmaceuticals launches urinary tract infection product Microdox - Sonoma Pharmaceuticals has launched Microdox, an urinary tract infection catheter and bladder rinse in New Zealand, Australia and South Africa. Microdox is a super-oxidized solution based on Sonoma's patented Microcyn Technology intended to treat and prevent infections in the urinary tract and bladder. Microdox is currently available through Sonoma's partners, Te Arai BioFarma in New Zealand and Australia, and NuAngle in South Africa.

06:08 EDT BioNTech sees FY22 CapEx EUR450M-EUR550M - Sees FY22 tax rate approximately 28%.

06:06 EDT Citi selling Its consumer businesses in India to Axis Bank for $1.6B - Citi has reached an agreement with Axis Bank for the sale of Citi's consumer businesses in India. Axis was selected by Citi following a competitive auction process. The transaction comprises the sale of the consumer banking businesses of Citibank India, which includes credit cards, retail banking, wealth management and consumer loans. The transaction also includes the sale of the consumer business of Citi's non-banking financial company, Citicorp Finance India, comprising the asset-backed financing business, which includes commercial vehicle and construction equipment loans, as well as the personal loans portfolio. It excludes Citi's institutional client businesses in India. The transaction will also include approximately 3,600 Citi employees supporting the consumer businesses in India, who will transfer to Axis upon completion of the proposed transaction. Axis will pay to Citi cash consideration of approximately $1.6B for the acquisition of the consumer business, subject to customary closing adjustments. The transaction is expected to close in the first half of calendar year 2023 subject to requisite regulatory approvals. Upon closing, Citi expects the transaction to result in the release of approximately $800M of allocated tangible common equity. Citi's global exit from its consumer banking franchises in 13 markets across Asia and EMEA is expected to release approximately $7B of allocated tangible common equity over time. Citi has been present in India since 1902. Citi serves over 2000 international corporations in India and 300+ large domestic companies and financial institutions. In 2021, in India Citi has helped raise over $29B of capital across over 40 equity and debt transactions and provided strategic M&A advisory on seven announced transactions, amounting to over $5B. Citi also handles 8% of India's trade flows and 5% of the country's electronic payments flows. Citi supports foreign portfolio investors to get access to Indian markets - managing about a third of their activities in India as a custodian.

06:03 EDT BioNTech expects to authorize $1.5B share repurchase program over next 2 years

05:21 EDT Titan International to sell Australian wheel business for A$23M - Titan International has entered into a definitive agreement for the sale of its Australian wheel business, to OTR Tyres, a national tire, wheel and service provider. The closing date is expected to be Thursday, March 31. The sale includes gross proceeds and cash to be repatriated of approximately A$23M, and the assumption of all liabilities, including employee and lease obligations. The purchase price is subject to customary post-closing review and potential adjustments related to target working capital, along with the release of certain restricted cash related to lease guarantees. The proceeds related to the transaction are expected to be primarily utilized to pay down debt and pay advisory fees.

05:15 EDT Samsung, Western Digital to collaborate on storage technologies - Samsung (SSNLF) and Western Digital (WDC) announced that they have signed a memorandum of understanding, or MOU, for a collaboration to standardize and drive broad adoption of next-generation data placement, processing and fabrics storage technologies. The companies will initially focus on aligning their efforts and creating an ecosystem for Zoned Storage solutions. These steps will enable the industry to focus on countless applications. In addition, this collaboration is expected to serve as a starting point to expand zone-based device interfaces, as well as storage devices with enhanced data placement and processing technologies. At a later stage, these initiatives will be expanded to include other emerging D2PF technologies such as computational storage and storage fabrics including NVMe over Fabrics.

05:09 EDT Partner Communications gets Minister of Communications approval for share sale - Partner Communications reported, that further to the company's press releases dated November 25, 2021 and December 16, 2021 and Item 3D.3a in the company's annual report on Form 20-F for 2021, on March 29, the Minister of Communications' approval was received for the transfer of control and of the means of control and the change of the institutional investors or their substitutes in connection with a transaction for the purchase of 49,862,000 of the company's shares held by S.B. Telecom constituting approximately 27% of the company's issued and outstanding share capital by Amphissa Holdings. According to the approval, the general partner of Amphissa Holdings is Israel Lighterage and Supply Co., which is 50% owned by Shlomo Rodav and 50% owned by Roni Gat and members of his family, and the limited partners are mostly institutional investors from the Phoenix, Clal and Menora groups. The approval allows Avi Gabbay to join the partnership in the future as a limited partner and as general partner, directly or through a company under his control. Further to the approval, the company was notified that the transaction is expected to be completed on April 4.